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Essays on Health Care Quality and Access: Cancer Care Disparities, Composite Measure 
Development, and Geographic Variations in Electronic Health Record Adoption 
 
Abstract 
 
Racial/ethnic disparities in cancer care are well documented in the research literature; 
however, less is known about the extent and potential source of cancer care disparities in the 
Veterans Health Administration (VA).  In my first paper, I use logistic regression and hospital 
fixed effects models to examine racial disparities in 20 cancer-related quality measures and the 
extent to which racial differences in site of care explain VA cancer care disparities. I found 
evidence of racial disparities in 7 out of 20 cancer-related quality measures.  In general, these 
disparities were primarily driven by racial differences in care for black and white patients within 
the same VA hospital, rather than racial differences in site of care.  
There has been limited use of composite measures for cancer care quality 
measurement.  In my second paper, I employ and compare several grouping (i.e., empirical 
factor analysis vs. cancer-specific vs. care-modality-specific) and weighting (i.e., fixed- vs. 
opportunity-weighting) approaches for computing VA hospital-level composite measures of 
cancer care quality.  I assess correlations among composites and estimate all-cause survival for 
colorectal and lung cancers as a function of composite scores.  The empirically-derived care 
dimensions summarized relationships among care processes and reflected a combination of 
cancer-specific and care-modality-specific composites.  Patterns in predicting patient survival 
were similar for composites with comparable measure compositions.  In addition, opportunity-
based composites were subject to variation reflecting differences in the case mix of eligible 
patients at each hospital rather than actual differences in quality.   
Professor Thomas McGuire     Cleo Alda Samuel 
Professor Alan Zaslavsky 
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In my third paper, I assess geographic variations in electronic health record (EHR) 
adoption among primary care providers (PCPs) enrolled in the Regional Extension Center 
(REC) program.  I employ hierarchical models to examine associations between EHR adoption 
among REC-enrolled PCPs and several county-level measures.  I found that community health 
center presence, Medicaid enrollment, and Medicare Advantage enrollment within the county 
were positively associated with EHR adoption.  However, health professional shortage area 
status and minority concentration were negatively associated with EHR adoption.  My findings 
suggest that federal efforts, such as the Medicare and Medicaid EHR incentive programs, may 
be encouraging EHR adoption.  Still, some geographic disparities in EHR adoption remain a 
concern. 
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Chapter 1 
Racial Disparities in Cancer Care in the Veterans Affairs Healthcare System  
and the Role of Site of Care  
 
I.  INTRODUCTION 
 Cancer is the second leading cause of death in the US.1 Research indicates that overall 
cancer incidence and mortality rates are higher among blacks relative to whites.2  This is true 
despite major advancements in cancer care and outcomes in recent decades.  Past research 
indicates that racial/ethnic disparities in care and outcomes exist for many conditions, but that 
these disparities are attenuated in the Veterans Affairs (VA) health care system, where financial 
barriers to care are substantially reduced for eligible veterans.3-5  However, less is known about 
the extent of cancer-related disparities in the VA hospital system. 
The few studies that have assessed cancer disparities in the VA have generated mixed 
findings, with some studies finding disparities in cancer care and others reporting equitable care 
for black and white veterans.3,4,6-11  Moreover, these studies offer little insight into the factors 
that might account for any observed disparities in cancer care and outcomes across the entire 
VA.   Hospital care in the U.S. is highly concentrated for black Americans, with facilities caring 
for a larger share of black patients (minority-serving institutions) often providing lower quality 
care than non-minority serving institutions.12,13  In addition, racial differences in hospital site of 
care have also been linked to racial disparities in receipt of recommended care and 
outcomes.12,14,15 
 In this study, we build upon and extend earlier work on cancer disparities by assessing 
racial disparities in cancer care and outcomes in the VA health care system.  We also explore 
the extent to which racial differences in site of care explain any observed disparities in cancer 
care and outcomes in the VA.  We use VA Central Cancer Registry (VACCR) data and VA 
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administrative data.  These data sources capture patient-level characteristics and treatment 
patterns for all VA cancer patients.  
 
II. BACKGROUND 
Evidence of Racial/Ethnic Disparities in Cancer Care and Outcomes 
Compared with all other racial/ethnic groups, blacks in the US experience the greatest 
burden of death from all of the most common forms of cancer.16  Between 2000-2004 the age-
adjusted overall mortality rate (deaths per 100,000) for blacks was 238.8, compared to 190.7 for 
whites;2 and recent evidence indicates that disparities in cancer care and outcomes have 
persisted over time.17,18  
A variety of factors contribute to the excess burden of cancer mortality among blacks, 
including differential access to health care, socioeconomic status, and racial differences in 
receipt of recommended care.2  In terms of cancer-related care processes, blacks generally lag 
behind whites in receipt of recommended cancer screening and early diagnosis.  In 2009, Virnig 
et al. examined racial differences in stage of diagnosis across 34 types of cancer and found that 
blacks were diagnosed later than whites for 31 of the 34 cancer types/sites.19  Black cancer 
patients are also less likely to receive life-prolonging chemotherapy and treatments.  For 
example, one study showed that compared to 52.4% of white non-Hodgkin lymphoma (NHL) 
patients, only 43.2% of black NHL patients received recommended chemotherapy.20  Several 
studies have also reported lower rates of curative surgery among black early-stage (stage I/II) 
non-small cell lung cancer (NSCLC) patients.  In a study on racial differences in the treatment of 
early-stage NSCLC patients, Bach et al. showed that curative surgery rates were 12.7 
percentage points lower for older black patients relative to older white patients and that 5-year 
survival rates were also much lower for blacks.21  In addition, their study revealed that the racial 
disparity in survival was largely attributed to racial differences in receipt of curative surgery.   
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 Thus, it appears that black-white differences in cancer survival are partly attributable to 
racial differences in receipt of recommended care. And so, identifying the factors driving both, 
racial disparities in receipt of recommended care and cancer survival, is critical to efforts aimed 
at mitigating disparities in cancer outcomes. 
 
The VA Hospital System: Context, Quality of Cancer Care, and Disparities 
 The Veterans Health Administration (VA) operates the largest integrated health care 
system in the United States.  Today, the VA consists of 152 medical centers and close to 1,400 
community-based outpatient clinics, community living centers, Vet Centers, and domicilaries 
serving over 8.3 million veterans annually.22   
 Cancer is the second leading cause of death among veterans.23,24  Recent work 
suggests that cancer care in the VA is comparable to or of better quality than care provided to 
insured individuals in the private-sector.25-27  Past research also indicates that racial/ethnic 
disparities in care and outcomes are less pronounced in the VA, where financial barriers to care 
are substantially reduced for eligible veterans;3-5  however, these studies have typically focused 
on disparities in cardiovascular disease, mental health, and preventive/ambulatory care.28  Less 
is known about the extent and source of VA cancer care disparities. The few studies that have 
assessed cancer disparities in the VA have generated mixed findings, with some studies 
observing disparities in cancer care and others reporting equitable care for black and white 
veterans.3,4,6-11  In addition, most of these studies have typically focused on a few cancer types 
and/or cancer care quality measures or have examined care in a limited number of VA Medical 
Centers.   
 
Potential Sources of Racial/Ethnic Disparities in Health Care  
 The Institute of Medicine’s (IOM) 2003 report, Unequal Treatment: Confronting Racial 
and Ethnic Disparities in Health Care, documented the extent of racial/ethnic health care 
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disparities in the US.29  The IOM's definition of health care disparities accounts for all 
racial/ethnic differences in care that are mediated through factors other than patient preferences 
and clinical appropriateness.  This definition acknowledges that minorities typically have lower 
socioeconomic profiles than whites, that such differences can influence health care quality and 
use, and as a result, includes such racial differences in socioeconomic status (e.g., income, 
education) in the accounting of total disparities.  Thus, adjusting for socioeconomic status in 
statistical models estimating racial disparities may reduce or eliminate the estimated 
independent effect of race on care, however, this does not diminish the measure of racial/ethnic 
disparity.30 
 Unequal Treatment also highlighted potential sources of racial and ethnic health care 
disparities including patient characteristics, the clinical encounter, and health system level 
factors. Patient characteristics such as racial and ethnic differences in financial resources, 
health care seeking behaviors, and health literacy can contribute to health care disparities.  
Uncertainty in the clinical encounter can contribute to doctors’ reliance on stereotypes and 
biases when making diagnostic and treatment decisions.  Finally, health care system level 
factors such as language barriers, care fragmentation, and differential availability of services 
can also contribute to racial/ethnic health care disparities.   
 Of particular interest in this research study is the potential role of health system level 
factors and whether cancer disparities are explained by differential patterns in care at facilities 
where black and white cancer patients receive care. 
 
Racial Differences in Site of Care as a Potential Source of Health Care Disparities 
 Past studies indicate that a small share of hospitals provide care to a disproportionately 
large share of black patients. Approximately 5% of non-federal hospitals provide care to over 
40% of all black elderly patients in the US.12  This pattern of racially concentrated care has also 
been observed in the VA system, where 28% of hospitals provide care to over 75% of black 
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veterans.13  In addition to care being highly concentrated for blacks, research also indicates that 
hospitals serving a disproportionate share of black patients (minority-serving institutions) tend to 
perform worse along quality indicators relative to hospitals serving lower volumes of black 
patients (non-minority serving institutions). For example, in a study on the racial concentration 
and quality of hospitals that disproportionately care for black patients, Jha et al. found that 
minority-serving institutions performed worse along quality measures related to acute 
myocardial infarction (AMI) and pneumonia care quality.12  In another study on racial differences 
in definitive breast cancer therapy, Keating et al. found that older black women were less likely 
than older white women to undergo surgery at hospitals with higher rates of radiation following 
breast-conserving surgery.14  Similarly, in a 2008 study on racial disparities in lung cancer, 
Lathan et al. found that older early-stage NSCLC patients receiving care at hospitals with high 
proportions of black patients (black racial composition >= 30%) were less likely to undergo 
curative surgery.15 
 Collectively, these studies offer some indication that racial disparities in quality of care 
are at least partly driven by "between-hospital" differences or differences in where black and 
white patients receive care.  Assessing the relative contributions of within-hospital differences 
(differences in care and treatment for black and white patients treated at the same hospital) and 
between-hospital differences to racial disparities in care can help inform policies and 
interventions aimed at addressing racial disparities in care.   
 
Research Aims 
In this study, we assess the extent of race-based cancer care disparities in the VA 
across a broad range of cancer types and measures.  In addition, we examine whether racial 
differences in where cancer patients were treated explain any observed disparities in cancer 
care and outcomes.  In particular, we were interested in determining whether cancer care 
disparities were mainly attributable to between- or within-hospital differences in the VA.    
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III. METHODS 
Overview 
 We first computed unadjusted racial differences across 20 cancer-related process and 
outcome measures for veterans who received care in a VA Medical Center during 2001-2004.  
We then estimated a series of adjusted logistic regression models (1 per cancer site-specific 
measure) assessing whether patient race was associated with receipt of recommended cancer 
care and outcomes (Model 1).  Next, we adjusted for hospital fixed effects using conditional 
logistic regression models (Model 2).  We then compared the race effect in Model 1 to the race 
effect in Model 2 to determine the degree to which racial differences in care were due to within- 
or between-hospital differences.  Substantial changes in the magnitude of the race effect after 
adjustment for hospital fixed effects indicated that racial differences in site of care explained a 
substantial amount of the observed racial disparity in cancer care.  Little to no change in the 
race effect indicated that disparities in cancer care  were mainly driven by differences in care 
provided to black and white patients treated within the same hospital. 
 
Data Sources 
We obtained data on patients who were diagnosed with cancer and/or received their first 
course of cancer therapy in the VA during 2001-2004 from the VACCR.  The registry maintains 
information on patient demographics, tumor characteristics, and primary treatment for each 
incident cancer.  Registry data were linked with additional data from 2000-2005, including VA 
administrative data (inpatient, outpatient, pharmacy, and laboratory data), Medicare 
administrative data (for Medicare-eligible veterans), and pain score data from office visits.  
These data were also linked to the 2000 Census data to obtain zip code-level measures of 
socioeconomic status and the National Death Index to determine patient vital status through 
2005. 
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Cancer Cohorts 
We studied veterans with colorectal, lung, or prostate cancer, the most prevalent 
cancers among veterans.  We excluded small numbers of patients whose cancers were 
reported based on autopsy or death certificate or for whom no reporting source was available, 
patients for whom data were incomplete (e.g., missing month of diagnosis, no administrative 
data between 45 days before diagnosis through 195 days after diagnosis), or patients with 
histologic features suggesting a primary cancer other than the cancer of interest.26  We also 
restricted our cohorts to non-Hispanic black and white veterans because we were primarily 
interested in black-white differences in care and the number of patients in other racial/ethnic 
subgroups was small.  The final cohorts include 12,897 colorectal cancer patients (10,027 
colon, 2,870 rectal), 25,608 lung cancer patients, and 38,202 prostate cancer patients spanning 
118 VA Medical Centers.  
 
Cancer Care Performance Measures 
We consulted with oncology specialists to identify measures of quality along the 
continuum of cancer care.  In total, we assessed 20 cancer-related process and outcome 
measures26,27,31 reflecting evidence-based nationally recommended guidelines for colorectal 
cancer, lung cancer, prostate cancer, and palliative/supportive care across cancer types during 
the study period of 2001-2005.32-44  We also identified quality measures for hematological 
cancers, but did not include these measures in this analysis because the number of patients 
was too small to ensure adequate statistical power.  However, hematological cancer patients 
were included in the palliative/supportive care measure cohorts.   
Additional details about each measure and cohort eligibility are included in Table 1.1. 
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Table 1.1 Measures of Recommended Processes of Cancer Care and Outcomes 
Quality Measure Definition Cohort 
   
Colorectal Cancer   
Early Stage (Stage I/II vs. III/IV) 
at Presentation, Colon Cancer 
Patients diagnosed with stage I & II vs. 
stage III & IV colon cancer 
All patients with stage I-IV colon cancer. 
Early Stage (Stage I/II vs. III/IV) 
at Presentation, Rectal Cancer 
Patients diagnosed with stage I & II vs. 
stage III & IV rectal cancer 
All patients with stage I-IV rectal cancer. 
Curative Surgery for Stage I, II, 
or III Colon Cancer
32
 
Proportion of patients with Stage I, II, 
or III colon cancer who underwent 
curative resection within 180 days of 
diagnosis; polypectomy/local excision 
of the tumor for stage 1 T1 tumors that 
have well- or moderately differentiated 
tumor grades were also included 
All stage I/II/III colon cancer patients.  Patients had to be alive and 
not enrolled in a Medicare HMO through 180 days from surgery. 
Curative Surgery for Stage I, II, 
or III Rectal Cancer
33
 
Proportion of patients with Stage I, II, 
or III colon cancer who underwent 
curative resection within 180 days of 
diagnosis; polypectomy/local excision 
of the tumor for stage 1 T1 tumors that 
have well- or moderately differentiated 
tumor grades were also included 
All stage I/II/III rectal cancer patients.  Patients had to be alive and 
not enrolled in a Medicare HMO through 180 days from surgery. 
Adjuvant Chemotherapy for 
Stage III Colon Cancer
32
 
Receipt of adjuvant 5 fluorouracil or 
capecitabine within 90 days following 
curative-intent resection of stage III 
colon cancer 
All stage III colon cancer patients who underwent curative-intent 
resection.  Patients had to be alive and not enrolled in a Medicare 
HMO through 90 days from surgery. 
Adjuvant Chemotherapy and 
Radiation Therapy for Stage II 
or III Rectal Cancer
33
 
Receipt of both adjuvant 
chemotherapy with 5-fluorouracil or 
capecitabine and radiation therapy 
before or within 140 days following 
curative intent resection for stage II or 
III rectal cancer  
All stage II/III rectal cancer patients who underwent curative-intent 
resection.  Patients had to be alive and not enrolled in a Medicare 
HMO through 180 days from surgery. 
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Table 1.1 (Continued)     
   
Three-Year All Cause Survival 
for Colon Cancer 
Proportion of patients alive 3 years 
after the date of diagnosis 
All patients diagnosed with colon cancer during 2001 & 2002. 
Three-Year All Cause Survival 
for Rectal Cancer 
Proportion of patients alive 3 years 
after the date of diagnosis 
All patients diagnosed with rectal cancer during 2001 & 2002. 
   
Lung Cancer   
Curative Surgery for Stage I or 
II Non-Small Cell Lung Cancer
34
 
Pneumonectomy, lobectomy, or wedge 
or segmental resection within 180 days 
of diagnosis 
All stage I/II non-small cell lung cancer patients. Patients had to be 
alive and not enrolled in a Medicare HMO through 180 days from 
diagnosis. Patients were also included if they died within 180 days 
but underwent surgery. 
Mediastinal Evaluation for 
Stage I or II Non-Small Cell 
Lung Cancer
34
 
Mediastinal evaluation from 45 days 
before diagnosis through the date of 
surgery 
All stage I/II non-small cell lung cancer patients who underwent 
lobectomy or pneumonectomy. Patients had to be alive and not 
enrolled in a Medicare HMO through 180 days from surgery. 
Chemotherapy and/or Radiation 
for Resected Stage IIIA Non-
Small Cell Lung Cancer
34
 
Chemotherapy and/or radiation 
therapy from 30 days before diagnosis 
through 90 days after date of surgery 
All stage IIIA non-small cell lung cancer patients who underwent 
lobectomy or pneumonectomy or wedge resection.  Patients had to 
be alive and not enrolled in a Medicare HMO through 90 days from 
surgery. 
Chemotherapy and Radiation 
for Limited-Stage Small Cell 
Lung Cancer
35
 
Cisplatin or carboplatin and etoposide 
with concurrent radiation therapy within 
180 days of diagnosis; chemotherapy 
must start between the start and end 
dates of radiation therapy 
All limited-stage small cell lung cancer patients. Patients had to be 
alive through 45 days from diagnosis and not enrolled in a 
Medicare HMO through 180 days from diagnosis. 
One-Year All Cause Survival for 
Non-Small Cell Lung Cancer 
Proportion of patients alive 1 year after 
the date of diagnosis 
All patients with non-small cell lung cancer. 
One-Year All Cause Survival for 
Small Cell Lung Cancer 
Proportion of patients alive 1 year after 
the date of diagnosis 
All patients with small cell lung cancer. 
   
   
   
   
   
   
  
 
1
0
 
   
Table 1.1 (Continued)     
   
Prostate Cancer   
Androgen Ablation within 120 
Days for Men with Stage IV 
Prostate Cancer
37,38,40,41
 
Androgen deprivation therapy with a 
gonadotropin-releasing hormone 
(GnRH) agonist or bilateral 
orchiectomy within 120 days of 
diagnosis 
All prostate cancer patients with stage IV cancer at diagnosis. 
Patients had to be alive and not enrolled in a Medicare HMO 
through 120 days from diagnosis. 
Oral Anti-Androgen before 
Initiating Gonadotropin 
Releasing Hormone (GnRH) 
Agonist Therapy for Metastatic 
Prostate Cancer
36
 
Proportion of men with metastatic 
cancer who are started on GnRH 
agonist who also fill a prescription for 
an oral anti-androgen for at least 2 
weeks, beginning at least 1 week 
before first dose of GnRH agonist 
All prostate cancer patients with stage IV cancer at diagnosis who 
started a GnRH agonist. 
Adjuvant Androgen Deprivation 
Therapy for High-Risk Cancers 
Treated with Radiation 
Therapy
36
 
Proportion of patients with high-risk 
prostate cancer (gleason 8-10 or PSA 
>20 or stage T3 or greater) treated 
with radiation who also receive 
hormonal therapy (adjuvant or 
neoadjuvant) 
All patients with high risk, non-metastatic tumors treated with 
radiation therapy within 180 days of diagnosis. Patients were 
required to be alive and not enrolled in a Medicare HMO through 
180 days from diagnosis. We only included cases in 2001-2002 
because Gleason 7 tumors could not be distinguished from 
Gleason 8 tumors in 2003-2004. 
3-Dimensional Conformal 
Radiotherapy (3-D CRT) or 
Intensity-Modulated Radiation 
Therapy (IMRT) for Prostate 
Cancer Patients Treated with 
Electron Beam Radiation 
Therapy (EBRT)
36,39,42
 
Receipt of 3D-CRT or IMRT among 
men with local or regional prostate 
cancer who received external beam 
radiation therapy within 180 days of 
diagnosis 
All patients with local or regional prostate cancer at diagnosis who 
also had evidence of external beam radiation therapy in 
administrative data.  Patients had to be alive and not enrolled in a 
Medicare HMO through 180 days from diagnosis. 
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Table 1.1 (Continued)     
   
Palliative/Supportive Care   
Use of Potent Antiemetics for 
Highly-Emetogenic 
Chemotherapy
43
 
Receipt of 5-HT blockade 
(administered intravenously and/or 
orally) among patients treated with 
highly emetogenic chemotherapy. 5HT 
blockade assessed from 30 days 
before date of first dose of a highly 
emetogenic chemotherapy through 30 
days following last dose of the same 
chemotherapy 
All patients with colorectal cancer, lung cancer, prostate cancer, 
non-Hodgkins lymphoma, or multiple myeloma who are treated with 
one of the highly emetogenic chemotherapy drugs, including 
adriamycin, cisplatin, carbo-platin, cyclophosphamide, ifosphamide, 
idarubicin, epirubicin, daunorubicin. Patients could not be in a 
Medicare HMO during the time window of interest. 
Prescription of Narcotic Pain 
Medication for Advanced 
Cancer Patients in Pain
44
 
Opioid prescription filled among stage 
IV patients with 2 consecutive pain 
scores ≥5; script must be filled during 
the period between the 2 pain scores 
All patients with colorectal cancer, lung cancer, prostate cancer, 
non-Hodgkins lymphoma, or multiple myeloma diagnosed at stage 
IV who have 2 consecutive pain scores of ≥5 from 3-30 days apart 
with no lower pain score between and no hospitalization. Patients 
could not be in a Medicare HMO during the time window of interest. 
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Covariates 
The independent variable of primary interest was patient race/ethnicity (non-Hispanic 
black vs. non-Hispanic white).  Race/ethnicity was reported by the registry based on self-
identified information collected at VA enrollment; in the infrequent case where data were 
missing, registrars used medical record data.  Patient-level sociodemographic characteristics 
include age, sex, marital status, and area-level socioeconomic status based on the zip code of 
the patient’s residence (median household income, the percentage of college graduates, and 
the percentage of persons living below the poverty level).  Patient-level clinical characteristics 
include presence of comorbidities (measured using the Klabunde modification of the Charlson 
score45,46 separating chronic obstructive pulmonary disease [COPD] from the Charlson score for 
lung cancer patients), prior history of any cancer, year of diagnosis, stage of diagnosis, tumor 
size, and tumor grade.   
 
Analyses 
We first conducted descriptive analyses assessing racial differences in each process 
and outcome measure as well as in patient sociodemographic and clinical characteristics. We 
then categorized hospitals into deciles of hospital black racial concentration (i.e. the proportion 
of patients with cancer who are black); and for process and outcome measures exhibiting racial 
differences, we plotted rates of the measures for patients cared for at hospitals by deciles of 
hospital black racial concentration.  Next, we estimated bivariate regression models predicting 
hospital-level rates of each disparity measure as a function of hospital racial concentration.   
 
Modeling Approach.  We estimated a series of logistic regression models (1 per cancer 
site-specific performance measure) to assess the effect of patient race on the odds of receiving 
recommended care and survival (Model 1).  The covariates we examined varied slightly across 
models due to differences in the nature of our performance measures.  All models adjusted for 
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age, sex (except prostate cancer models), marital status, prior cancer history, Charlson 
comorbidity score, and diagnosis year.  All lung cancer models included COPD as a covariate.  
In models assessing treatment and survival, we also adjusted for tumor grade and stage, and 
survival models also adjusted for tumor size. We also adjusted for cancer type in the 
palliative/supportive care models.   
As described earlier, racial disparities in care can be attributed to a number of factors, 
including racial differences in where care is received (between-hospital differences) as well as 
differences in the care provided to individual patients at a given hospital (within-hospital 
differences).  A between-hospital explanation of racial disparities in care might highlight the 
disproportionate share of minority patients receiving care at lower quality hospitals while a 
within-hospital explanation might point to inequitable treatment patterns among patients of 
different racial backgrounds within the same facility.  Each race effect obtained from Model 1 in 
our analyses reflects a total effect of race (within-hospital+between-hospital differences) on the 
receipt of recommended cancer care (or survival) after adjusting for patient-level characteristics.  
To determine the extent of between- vs. within-hospital effects on disparities in cancer care, we 
estimated a second set of models where we also adjusted for hospital-level fixed effects using 
conditional logistic regression models (Model 2).  Hospital-level fixed effects models control for 
any hospital factors (between-hospital differences) that might be associated with cancer care 
(e.g., access to cancer specialists, availability of medical technologies).47,48  Thus, the race 
parameter estimates obtained the from hospital-level fixed effects models (Model 2) reflect the 
within-hospital component of the disparity and can be compared with the race parameter 
estimates obtained from Model 1 to make determinations regarding the extent of between- vs. 
within-hospital disparities in cancer care.   
 
Accounting for Socioeconomic Status.  In accordance with the IOM’s definition of health 
care disparities, we did not adjust for socioeconomic status in our main models.  Thus, our 
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disparity estimates reflect the independent effect of race and not a “residual direct effect” of race 
on care.  However, because understanding how disparities in care might arise is important to 
addressing health inequities, we conducted additional analyses to assess whether racial 
differences in socioeconomic status accounted for any observed disparities in cancer care and 
survival. 
 
Adjustment for Multiple Comparisons.  Lastly, we adjusted our model results for multiple 
comparisons using the Benjamini-Hochberg (B-H) procedure, a sequential approach to 
controlling the false discovery rate associated with multiple comparisons.  The B-H procedure 
has been shown to yield greater statistical power than the more widely used Bonferroni 
correction, which controls the family-wise error rate.49,50  In the B-H approach, p values obtained 
from a family of tests (family size=m) are ordered from largest to smallest and sequentially 
compared to a list of B-H critical values that range from α to α/m.  Use of the B-H approach has 
become quite widespread in the field of genetics and other life sciences, and for well over a 
decade, the National Center for Education Statistics has employed the B-H approach in 
reporting results from the National Assessment of Educational Progress49,51-54 
 
All analyses were conducted using SAS version 9.3. 
 
IV. RESULTS 
Unadjusted Racial Group Comparisons   
Table 1.2 shows characteristics of each cancer cohort by race.  Across all cancer 
cohorts, compared with white patients, black patients were younger, less likely to be married, 
and more likely to reside in areas with higher poverty, less college education, and lower median 
income.
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Table 1.2 Characteristics of Cancer Cohorts by Race 
   
Colorectal Lung Prostate 
   
         
   White Black White Black White Black 
   N =10,636 N =2,261 N =21,077 N =4,531 N =27,889 N =10,313 
Characteristics       
         
 Age - %       
  <60 yrs 19.7 27.9 22.2 29.7 19.3 30.1 
  60-64 yrs 13.0 10.0 15.1 11.7 16.4 15.4 
  65-69 yrs 14.5 11.6 16.4 13.5 21.0 18.1 
  ≥ 70 yrs 52.8 50.5 46.3 45.1 43.2 36.4 
         
 Gender - %       
  Female 1.8 1.6 1.7 1.5   
  Male 98.2 98.5 98.3 98.5   
         
 Marital Status - %       
  Unmarried 40.7 50.2 49.4 63.6 40.1 55.3 
  Married 56.2 47.5 48.0 34.7 57.4 43.0 
  Unknown 3.1 2.3 2.6 1.7 2.6 1.7 
         
 Prior History of Cancer - %       
  No 86.6 85.5 83.0 83.1 92.4 94.9 
  Yes 13.4 14.6 17.0 16.9 7.6 5.1 
         
 Charlson Comorbidity Score - %       
  0 52.1 54.0 61.4 62.2 62.6 61.6 
  1 28.1 26.7 22.4 21.6 25.2 24.4 
  2 11.4 11.2 9.6 9.1 8.0 8.1 
  3 + 8.3 8.2 6.6 7.2 4.2 5.8 
         
 Year of Diagnosis - %       
  2001 23.0 25.3 24.2 25.2 24.6 24.7 
  2002 25.2 24.6 25.0 24.6 25.3 24.6 
  2003 25.6 25.7 25.2 25.7 24.7 24.9 
  2004 26.2 24.4 25.6 24.5 25.4 25.8 
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Table 1.2  (Continued) 
        
 % Population ≥ 65 Yrs Living Below Poverty in 
Zip Code of Residence - % 
 
     
  Q1 (0 - <7.9%) 27.1 11.0 27.0 9.8 29.2 11.2 
  Q2 (7.9 - <12.8%) 26.6 13.6 26.2 13.4 27.4 15.4 
  Q3 (12.8 - <19.5%) 25.0 20.2 24.7 19.9 24.5 24.0 
  Q4 (19.5 - 76.9%) 15.5 51.0 16.9 53.7 13.2 45.0 
  Missing/Unknown 5.8 4.3 5.2 3.3 5.7 4.4 
         
 % Population College Graduates in Zip Code of 
Residence - % 
 
     
  Q1 (<15.9%) 21.9 33.3 22.1 32.1 21.4 32.3 
  Q2 (15.9-21.6%) 24.0 21.9 23.8 23.8 23.4 23.2 
  Q3 (21.6-30.0%) 23.8 21.1 24.4 20.9 23.8 21.6 
  Q4 (30.0-100.0%) 24.4 19.7 24.5 20.0 25.7 18.5 
  Missing/Unknown 5.8 4.1 5.2 3.2 5.7 4.4 
         
 Median Income in Zip Code of Residence- $ 45,919 39,347 45,722 38,456 46,055 39,859 
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Table 1.3 displays unadjusted rates for each cancer-related process and outcome 
measure stratified by race.  For 8 of the 20 quality measures (40%), black cancer patients had 
lower rates of recommended care or survival than white patients.  Of note, blacks exhibited 
higher unadjusted rates of receipt of oral anti-androgen before initiating gonadotropin releasing 
hormone (GnRH) agonist therapy for metastatic prostate cancer. 
Overall, about one quarter of VA hospitals (N=30 hospitals) cared for close to 70% of all 
black cancer patients in the VA.  Among hospitals in the lowest decile of black racial 
concentration, 0% to 1% of their cancer patients were black, compared with 45% to 72% of 
cancer patients in hospitals in the highest decile.  Hospital black racial concentration was not 
associated with receipt of recommended care for 6 of the 8 measures (75%) exhibiting lower 
unadjusted rates for blacks relative to whites, including curative surgery for stage I/II/III rectal 
cancer (P=.54, Figure 1.1, Panel A).  We did observe a statistically significant association 
between the proportion of black cancer patients at each hospital and receipt of 3-dimensional 
conformal radiation therapy or intensity-modulated radiation therapy for prostate cancer patients 
treated with external-beam radiation therapy (3-D-CRT/IMRT) (P=.001, Figure 1.1, Panel B) and 
3-year all-cause survival for colon cancer (P=.02, data not shown).  We also observed greater 
receipt of oral anti-androgen before initiating GnRH agonist therapy for metastatic prostate 
cancer at hospitals with more black patients (P=.04, data not shown). 
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Table 1.3 Unadjusted and Adjusted Associations of Race with Recommended Cancer Care and Survival 
 
 
  Eligible 
Patients 
Performance 
Rates 
Unadjusted 
Differences 
Adjusted  
Odds Ratios   
       Model 1
†
 Model 2
‡
 
  White Black White Black Black-White Black vs. White Black vs. White 
Quality Measure (N) (N) (%) (%) (%) [95%CI] AOR [95% CI] AOR [95% CI] 
         
   Colon Cancer 
 
       
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Colon Cancer 
 
7262 1694 60.0 54.0 -6.0 [-8.6,-3.4]*    0.80 [0.72, 0.90]*   0.78 [0.70, 0.89]* 
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Rectal Cancer 
 
2123 336 63.2 59.2 -3.9 [-9.5, 1.6] 0.87 [0.68, 1.11] 0.87 [0.66, 1.15] 
 Curative Surgery for Stage I, II, or III  
Colon Cancer 
 
5375 1173 93.4 91.1 -2.2 [-3.8,-0.6]* 0.76 [0.58, 0.98]* 0.82 [0.61, 1.12] 
 Curative Surgery for Stage I, II, or III  
Rectal Cancer 
 
1636 251 79.2 67.3 -11.9 [-17.4,-6.4]*   0.57 [0.41, 0.78]*   0.57 [0.39, 0.82]* 
 Adjuvant Chemotherapy for Stage III  
Colon Cancer  
 
1381 343 70.2 65.0 -5.2 [-10.7, 0.2] 0.75 [0.58,0.98]* 0.87 [0.64, 1.18] 
 Adjuvant Chemotherapy and Radiation 
Therapy for Stage II or III Rectal Cancer 
 
723 108 74.0 79.6 5.6 [-3.2, 14.4] 1.49 [0.87, 2.53] 1.39 [0.73, 2.64] 
 Three-Year All Cause Survival for  
Colon Cancer ¶ 
 
3745 897 61.2 53.3 -7.9 [-11.5,-4.3]*   0.75 [0.62, 0.89]* 0.78 [0.64, 0.96]* 
 Three-Year All Cause Survival for  
Rectal Cancer ¶ 
 
1122 179 57.8 48.0 -9.7 [-17.5,-1.9]*   0.61 [0.42, 0.87]* 0.66 [0.43, 1.00] 
   Lung Cancer 
 
       
 Curative Surgery for Stage I or II Non-
Small Cell Lung Cancer 
 
3653 723 60.9 48.6 -12.4 [-16.3,-8.5]*   0.50 [0.41, 0.60]*   0.52 [0.41, 0.64]* 
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Table 1.3 (Continued) 
         
 Mediastinal Evaluation for Stage I or II  
Non-Small Cell Lung Cancer 
 
1956 298 88.2 86.2 -2.0 [-6.0, 2.0] 0.75 [0.52, 1.09] 0.92 [0.59, 1.44] 
 Chemotherapy and/or Radiation for 
Resected Stage IIIA Non-Small Cell 
Lung Cancer 
 
324 65 69.8 78.5 8.7 [-3.4, 20.8] 1.67 [0.86, 3.24] 1.35 [0.60, 3.05] 
 Chemotherapy and Radiation for  
Limited-Stage Small Cell Lung Cancer 
 
981 141 60.5 58.9 -1.6 [-10.2, 7.1] 0.96 [0.66, 1.41] 0.80 [0.51, 1.25] 
 One-Year All Cause Survival for Non-
Small Cell Lung Cancer 
 
17848 4059 40.6 39.5 -1.1 [-2.80,0.6] 1.06 [0.98, 1.15] 1.05 [0.96, 1.15] 
 One-Year All Cause Survival for Small 
Cell Lung Cancer 
 
3203 465 26.6 26.2 -0.4 [-4.6, 4.0] 1.04 [0.82, 1.33] 1.07 [0.82, 1.39] 
   Prostate Cancer 
 
       
 Androgen Ablation within 120 Days for 
Men with Stage IV Prostate Cancer 
 
1014 571 73.8 74.8 1.0 [-3.5, 5.5] 1.08 [0.84, 1.37] 0.99 [0.73, 1.33] 
 Oral Anti-Androgen before Initiating 
GnRH Agonist Therapy for Metastatic  
Prostate Cancer 
 
916 535 78.4 83.2 4.8 [5.4, 9.1]* 1.34 [1.01, 1.77]* 0.99 [0.70, 1.41] 
 Adjuvant Androgen Deprivation 
Therapy for High-Risk Cancers Treated 
with Radiation Therapy 
 
2853 970 56.5 55.5 -1.0 [-4.6, 2.6] 1.01 [0.87, 1.18] 0.86 [0.72, 1.04] 
 3-D CRT or IMRT for Prostate Cancer  
Patients Treated with EBRT 
 
5731 2056 64.3 48.0  -16.3 [-18.8,-3.9]*   0.53 [0.47, 0.59]*   0.75 [0.65, 0.87]* 
   Palliative/Supportive Care 
 
       
 Use of Potent Antiemetics for  
Highly-Emetogenic Chemotherapy 
 
 
8579 1898 71.6 69.0 -2.6 [-4.8,-0.3]*   0.87 [0.78, 0.98]* 0.95 [0.82, 1.10] 
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Table 1.3 (Continued) 
         
 Prescription of Narcotic Pain Medication 
for Advanced Cancer Patients in Pain 
 
2030 638 68.3 67.9 -0.5 [-4.6, 3.7] 1.04 [0.85, 1.27] 1.04 [0.83, 1.31] 
          
AOR – Adjusted Odds Ratio   
GnRH – Gonadotropin Releasing Hormone 
3-D CRT – 3-Dimensional Conformal Radiation Therapy 
IMRT – Intensity Modulated Radiation Therapy 
EBRT – External Beam Radiation Therapy 
† Model 1 corresponds to adjusted logistic regression models excluding hospital fixed effects.  
‡ Model 2 corresponds to adjusted logistic regression models including hospital fixed effects. 
All models adjusted for age, sex (except prostate cancer models), marital status, prior cancer history, Charlson comorbidity score, and year of 
diagnosis.  Lung cancer models also included chronic obstructive pulmonary disease (COPD) as a covariate, and for this group the Charlson 
score was calculated without COPD. Treatment and survival models adjusted for tumor grade and stage, and survival models also adjusted for 
tumor size. Palliative/supportive care models adjusted for cancer type.   
* indicates unadjusted difference or AOR is statistically significant at p<.05. 
Boldface* indicates AOR is statistically significant after applying Benjamini-Hochberg multiple comparisons adjustment.  
¶ Three-year survival for colon and rectal cancers captures patients diagnosed during 2001 & 2002. 
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Panel A. Curative Surgery for Stage I, II, III Rectal Cancer 
 
 
              
Panel B. 3-D-CRT/IMRT for Prostate Cancer
 
 
 
Figure 1.1 Hospital-level rates of recommended treatment plotted against deciles of black racial 
concentration across VA hospitals for two example measures. No association was noted in bivariate 
regression analyses assessing the relationship between hospital-level rates of curative surgery for stage 
I/II/III rectal cancer and black racial concentration across VA hospitals (Panel A).  A statistically significant 
association was observed between hospital-level rates of 3-dimensional conformal radiation therapy or 
intensity-modulated radiation therapy for prostate cancer patients treated with external-beam radiation 
therapy (3-D-CRT/IMRT) and black racial concentration across VA hospitals (Panel B).  Test statistics are 
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Figure 1.1 (Continued) 
from bivariate regression analyses predicting hospital-level rates of each measure as a function of 
hospital racial concentration are reported in each panel. 
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Main Adjusted Models 
Of the 20 quality measures examined using covariate-adjusted logistic regression 
analyses, 9 measures initially exhibited statistically significant lower rates of treatment for black 
vs. white patients; however, after adjustment for multiple comparisons, only 7 of these 
associations remained statistically significant.  Compared with white patients, black patients had 
less early-stage diagnosis of colon cancer (adjusted odds ratio [AOR]=.80; 95%CI=.72-.90), less 
curative surgery for stage I/II/III rectal cancer ([AOR]=.57; 95%CI=.41-.78), lower 3-year all-
cause survival for colon cancer ([AOR]=75; 95%CI=.62-.89) and rectal cancer ([AOR]=.61; 
95%CI=.42-.87), less curative surgery for early-stage non-small cell lung cancer ([AOR]=.50; 
95%CI=.41-.60), less 3-D-CRT/IMRT ([AOR]=.53; 95%CI=.47-.59), and were less likely to 
receive potent antiemetics for highly emetogenic chemotherapy ([AOR]=.87; 95%CI=.78-.98) 
(Table 1.3, Model 1; see Appendix Table 4.1 for detailed results from Benjamini-Hochberg 
multiple comparisons adjustment). 
For 5 of these 7 quality measures where we observed lower odds of recommended care 
for black vs. white patients, additional adjustment for VA hospital fixed effects explained a very 
small portion (0% to 13%) of the observed racial gaps in performance (Table 1.3, Model 2).  In 
the case of potent antiemetics for patients receiving highly emetogenic chemotherapy, the race-
associated odds ratio changed from a statistically significant .87 [95%CI=.78-.98] to a non-
statistically significant .95 [95% CI=.82-1.10] after adjustment for hospital fixed effects.  
Adjustment for hospital fixed effects had a substantial impact on 1 measure, receipt of 3-D-
CRT/IMRT, where the race-associated odds ratio changed from .53 [95%CI=.47-.59] to .75 
[95%CI=.65-.87] after adjusting for site of care.   
Of note, we observed 1 measure where black patients had higher rates in adjusted 
analyses: receipt of oral anti-androgens before initiating GnRH agonist therapy for metastatic 
prostate cancer ([AOR]=1.34; 95%CI=1.01-1.77); and this higher rate was completely explained 
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by site of care ([AOR]=0.99; 95%CI=0.70-1.41).  However, the association in the first model was 
not statistically significant after adjustment for multiple comparisons.    
 
Models Adjusting for Socioeconomic Status   
Additional adjustment for area-level socioeconomic status (median household income, 
percentage of college graduates, and percentage of persons living below the poverty level) in 
separate analyses accounted for a relatively small portion (2% to 23%) of the observed racial 
gaps in performance and yielded estimates that were generally consistent with our overall 
results (see Appendix Table 4.2). 
 
IV. DISCUSSION 
 We assessed racial disparities in the quality of cancer care and outcomes within the VA 
health care system and the extent to which site of care accounted for any observed disparities 
in care and outcomes.  For 13 of the 20 quality measures (65%) examined, black and white 
patients appeared to receive similar levels of care.  These findings are consistent with previous 
research suggesting that disparities in care are mitigated in the VA.3,4  However, we did observe 
racial disparities in several cancer care measures.  Adjustment for socioeconomic status had 
relatively little impact on racial disparities in care and survival. This finding may reflect the “equal 
access” nature of the VA which reduces financial barriers to care for veterans and ultimately 
helps to lessen potential socioeconomic disparities in care.  
 Prior studies indicate that in the private sector, racial disparities in care are often driven 
by differences in where black and white patients receive care.15,47,55  For example, one national 
study of racial disparities in AMI treatment and outcomes among Medicare beneficiaries found 
that racial disparities in non-surgical medical treatments and outcomes substantially narrowed 
after adjusting for site of care.47  This site of care explanation for health care disparities is 
plausible given the high degree of racial concentration in U.S. hospital care as well as research 
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evidence indicating lower quality care among hospitals treating a higher proportion of black 
patients.12,14,15  Few studies have examined the association between health care disparities and 
site of care in the VA setting; those that have are consistent with our study, suggesting that 
health care disparities are explained more by within-hospital differences than between-hospital 
differences in the VA.  One study examining disparities in 30-day mortality rates across 6 
conditions (AMI, hip fracture, stroke, congestive heart failure, gastrointestinal hemorrhage, and 
pneumonia) found that for most conditions, mortality rates were similar among minority and non-
minority serving hospitals in the VA, and there was very little variation in the magnitude of 
disparities across hospitals.13  A more recent study assessing the quality of VA 
ambulatory/preventive care for diabetes, cardiovascular disease, hypertension, and cancer 
screening found that racial disparities were mainly driven by within-hospital differences.56  There 
remain high levels of racial concentration within relatively few hospitals in the VA.  However, we 
found little evidence to suggest that differences in where black and white cancer patients 
obtained care contributed to disparities in cancer care.  This lack of between-hospital disparities 
could be a result of ongoing system-wide quality initiatives undertaken by the VA. 
 Nevertheless, we observed some evidence of between-hospital differences in care for 2 
measures.  In the case of 3-D-CRT/IMRT, we observed a substantial between-hospital effect 
that accounted for nearly half of a relatively large adjusted racial gap in care.  This finding is 
likely attributable to differences in the timing of adoption of these advanced radiation therapy 
techniques across VA hospitals.  Adoption of 3-D-CRT and/or IMRT involves large investments 
in expensive medical equipment and the hiring of specialized staff,57 which may be delayed in a 
system with a fixed budget and without financial incentives to adopt new technologies as in the 
private sector.  The National Comprehensive Cancer Network guidelines began recommending 
use of 3-D-CRT in 2001.  Direct communication with individual VA hospitals revealed that nearly 
all VA hospitals had adopted 3-D-CRT/IMRT by 2006.  Our findings suggest that the hospitals 
where more black prostate cancer patients received care may have lagged behind other 
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hospitals in the adoption of 3-D-CRT/IMRT.  We also observed some evidence that smaller 
racial differences in receipt of potent antiemetics for highly emetogenic chemotherapy may be 
partly explained by site of care; it will be important for the VA to be certain that there are no 
differences in the availability of these medications that could explain these results. 
 
Limitations 
Our study’s strengths include the comprehensive measurement of cancer care quality, 
using both process and outcome measures, across the entire VA.  We also accounted for both 
total race effects and residual direct effects of race on cancer care.  To ensure accurate 
accounting of total racial disparities in care, future disparities studies should incorporate 
modeling approaches that reflect the IOM definition of racial disparities in health care.  
Furthermore, to our knowledge, no other study has explored site of care explanations for VA 
cancer care disparities.   
The study’s limitations include the focus on black and white veterans diagnosed with 
cancer in the first half of the last decade; the findings may not necessarily generalize to other 
racial/ethnic groups or patients with more recent diagnoses. Although more recent data would 
be ideal, other research suggests that disparities in cancer care and outcomes have continued 
to persist over time in the VA and the private sector.9,17,18,58 In particular, racial disparities in 
surgical treatment and survival among cancer patients remain a challenge for the VA.9,28,59  Our 
study, which distinguishes between the within-hospital and between-hospital sources of these 
health care inequities, therefore remains relevant and important to understanding cancer-related 
disparities in the VA. 
Second, we studied quality across 4 common types of cancer.  It is unclear whether 
these findings would generalize to other types of cancer, particularly less common forms.  Third, 
we assessed socioeconomic status using area-level measures due to the unavailability of 
reliable patient-level socioeconomic status data.  Although area-level measures are often used 
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when individual-level socioeconomic status measures are unavailable, past research indicates 
that area-level measures provide complementary contextual information on socioeconomic 
status and may not fully capture socioeconomic effects at the individual-level.60  In addition, we 
were unable to account for additional patient-level factors that could impact the treatment 
decision-making process, such as racial differences in preferences for treatment and 
performance status.   
Also, we used Medicare claims data to capture out of VA care by Medicare-eligible 
veterans; however, we may have missed care outside of the VA by veterans with private 
insurance who were not Medicare eligible.  Still, other evidence suggests that older veterans 
with cancers diagnosed and/or treated in the VA receive very little cancer surgery outside of the 
VA61 and in exploratory analyses, we also observed that few older VA patients received 
chemotherapy or radiation therapy outside of the VA.  Finally, low statistical power may have 
obscured true racial differences in care for some measures with smaller cohorts like 
chemotherapy and/or radiation for resected stage IIIA non-small cell lung cancer.  However, 
post-hoc power analyses revealed that most of our measure cohorts included a sufficiently large 
number of patients to detect at least a 10 percentage-point absolute difference in care by race. 
 
Conclusion 
Racial disparities in cancer care quality and outcomes in the VA were present for about 
a third of the measures assessed in this study.  In general, these disparities were primarily 
driven by racial differences in care for black and white patients within the same hospital, rather 
than racial differences in where care was received. Future efforts should focus on 
understanding the sources of these within-hospital disparities.  However, differential patterns in 
the adoption of some new technologies and use of medications across VA hospitals are 
potential sources of cancer disparities that deserve further exploration.    
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Chapter 2 
Developing and Evaluating Composite Measures of Cancer Care Quality 
 
I. INTRODUCTION 
Measuring and improving health care quality are important goals of health services 
research; however, the proliferation of quality indicators in recent years has created challenges 
for groups interested in using quality data (e.g., patients, providers, payers) for decision-making 
and/or quality improvement purposes.  To address this issue, many health services researchers 
have advocated wider use of summary or “composite” measures, particularly in the domains of 
ambulatory, surgical, and cardiac care.  However, use of composite measures of cancer care 
quality has been limited.  Cancer care is highly complex and typically involves specialists from 
multiple disciplines providing cancer- and stage-specific care along the cancer care continuum.  
To be useful, cancer care composite measures should account for these various aspects of 
cancer care.  
In research and practice, measures have commonly been grouped according to medical 
condition (e.g., heart disease, diabetes) or care-modality (e.g., surgical care quality) and 
combined using a variety of techniques.1-5  For example, the composite measures developed for 
the Centers for Medicare and Medicaid Services (CMS) Premier Hospital Quality Incentive 
Demonstration (HQID) are condition-specific and computed using opportunity-based scoring 
models.2  Given the complexity of cancer care, it is unclear whether condition-specific (i.e., 
cancer-specific) or care-modality-specific (e.g., screening, surgery) composites would be more 
appropriate for assessing cancer care quality.   
An alternative composite method, exploratory factor analysis, identifies groups of highly 
correlated measures that reflect an underlying construct (e.g., quality).  Composite measures 
defined using exploratory factor analysis may better represent the underlying dimensions of 
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care, and past work indicates that empirically-derived composites may be more strongly linked 
to patient outcomes than disease-specific composite measures.6   
 This study extends previous work on cancer care and quality measurement by 
comparing multiple approaches for developing composite quality measures for cancer care.  We 
use Veterans Affairs Central Cancer Registry (VACCR) data and VA patient-level administrative 
data.  These data sources capture patient-level characteristics and treatment patterns for all VA 
cancer patients.  
 
II. BACKGROUND 
Defining High Quality Cancer Care and Measuring Cancer Care Quality 
 The 1999 Institute of Medicine report, Ensuring Quality Cancer Care, documented that 
the quality of cancer care in the US is highly variable and many cancer patients do not receive 
recommended cancer care.7  Since the IOM report, more research has gone into measuring and 
improving the quality of cancer care.  More recently, the Affordable Care Act has prompted even 
greater interest in cancer care quality measurement by stipulating that 11 of the nation’s 
comprehensive cancer centers submit cancer care quality reports to CMS beginning in 2014.8  
However, despite growing interest in measurement and reporting of cancer care quality, there is 
still no general consensus on what actually constitutes "high quality" cancer care.  
 Health services researchers have typically assessed cancer care quality based on 
evaluations of individual quality performance indicators (e.g., receipt of curative surgery).9,10  
Such an approach to measuring cancer care quality may be too narrow given the complex 
nature of care along the cancer care continuum.  Processes along this continuum are often 
related and interdependent and include detection/screening, diagnosis, treatment, follow-up 
care, and end-of-life care.11  Failures at any point along this continuum can have a substantial 
impact on patient outcomes and overall care quality.12  Cancer type and stage add another layer 
of complexity to the assessment of cancer care quality because recommended care differs by 
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these characteristics.  In addition, cancer care is typically delivered by a multidisciplinary group 
of cancer care specialists and must be coordinated across disciplines, including surgery, 
medical oncology, radiation oncology, and often palliative care and primary care.  Because 
individual quality indicators typically assess a single aspect of care, such measures may not be 
sufficient for capturing the complexities and salient dimensions of cancer care quality. 
 
Use of Composite Measures in Health Services Research 
 Steady growth in the number of reported quality indicators has contributed to information 
overload among users of quality data.  One solution to this problem is to use composite 
measures that reduce the amount of data presented in quality reports by aggregating quality 
data into summary scores or indices.13  Composite measures also can overcome some of the 
statistical challenges associated with many individual quality indicators, including small sample 
sizes and consequent low reliability.  A composite measure that aggregates a group of related 
quality indicators with small samples may be more successful at discriminating true differences 
in care quality (i.e., “signal”) than the individual quality indicators of which it is comprised. 
Although use of composite measures of cancer care quality has been limited, disease-
specific composite measures have been developed for many conditions, including diabetes, 
cardiovascular disease, and pneumonia.2,3,5  Composite measures have also been employed to 
summarize quality for specific aspects of care such as treatment modality.  For example, in 
2009, Staiger et al. constructed composite measures of surgical quality performance for 
cardiovascular disease.  Compared with individual surgical quality indicators, the composite 
surgical quality measures were superior in terms of differentiating quality performance across 
hospitals, explaining variation in aortic valve replacement (AVR) mortality rates, and forecasting 
future AVR mortality rates.1 
 
Composite Approaches and Implications for Use in Cancer Care Quality Measurement 
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 Previous studies have demonstrated that hospital performance scores and rankings 
often vary depending on the grouping and weighting approach utilized to generate 
composites.14-16  Composite methods employed in the research literature include all-or-none 
scoring, linear combinations (e.g., simple averaging), and regression-based composites (see 
Appendix Table 4.3 for a description of common composite approaches).13,17   For nearly a 
decade, the CMS HQID program has employed opportunity-based scoring methods to generate 
composite quality measures for inpatient cardiovascular disease, pneumonia, and hip/knee 
replacement care.  In opportunity-based scoring, composites scores are generated by dividing 
the number of times a given set of care processes were actually performed (numerator) by the 
total number of opportunities for providing those recommended care processes to patients 
(denominator).  Thus, unlike simple averaging where each quality indicator is weighted by an 
equal and fixed amount, in opportunity-based scoring, each quality indicator is implicitly 
weighted in proportion to the percentage of eligible patients that comprise the denominator (i.e., 
opportunity-based weights), which may vary from provider to provider.  Approaches for 
conceptually grouping performance measures into composites also vary.  For example, 
composites can be condition-specific (e.g., HQID heart failure care composite), care-modality-
specific (e.g., surgical care composite), or reflect another grouping scheme that highlights other 
dimensions of care.   
Alternative approaches for generating composite measures include latent variable 
analysis methods, such as empirical factor analysis and principal components analysis, which 
are useful for identifying groups of highly correlated measures that may reflect some underlying 
latent trait (e.g., dimension of care quality).13,18  Factor-based composites are typically weighted 
by a fixed amount, the factor loading, based on the empirical relationships among quality 
indicators and their association with the hypothesized latent variable.  One earlier study found 
that cardiac care composites developed using latent variable analysis were more consistent with 
the organizational structure of cardiac care in hospitals and more predictive of patient outcomes 
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than composite measures generated using the CMS condition-specific opportunity-based 
scoring method.6   
Cancer care quality composites might be grouped according to condition/cancer type 
(e.g., lung cancer), care-modality (e.g., curative surgery), or empirical relationships among 
quality indicators (e.g., empirical factors).  Weighting methods for quality indicators (e.g., fixed 
weights vs. opportunity-based weights) also vary. 
 
Research Aims 
In this study, we explore and compare several approaches for computing composite 
measures of cancer care quality, specifically six types of composite measures: (1) fixed- and 
opportunity-weighted empirical factor composites, (2) fixed- and opportunity-weighted cancer-
specific composites, and (3) fixed- and opportunity-weighted care-modality-specific composites.  
We assess how well these composite measures summarize dimensions of cancer care quality 
and predict cancer patient survival.   
 
III. METHODS 
Overview 
We computed hospital-level rates of recommended care processes for colorectal, lung, 
and prostate cancers across VA hospitals.  Next, we generated six types of hospital-level 
composite measures of cancer care quality using fixed- and opportunity-based weighting 
approaches (see Table 2.1).  To compute fixed- and opportunity-weighted (1) empirical factor 
composites, we first conducted exploratory factor analyses to identify groups of highly correlated 
hospital-level cancer care process measures.  We then combined process measures based on 
either their fixed factor loading weights or opportunity-based weights.  We also computed two 
sets of (2) cancer-specific and (3) care-modality-specific composite measures using simple 
averaging (fixed weights) and opportunity-based weighting methods.  We compared the six 
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types of composite scores according to how well they summarized dimensions of cancer care 
quality and predicted patient-level survival.  We also assessed the extent to which differences in 
weighting methods (opportunity-based vs. fixed weights) contributed to variations in hospital 
composite scores. 
 
Table 2.1 Six Approaches for Generating Composite Measures of Cancer Care Quality 
 
 Weighting Approach 
 Opportunity Based Fixed 
Grouping Approach   
   
Empirical Factor Domain 
Opportunity-Weighted  
Empirical Factor Composites 
Fixed-Weighted (Factor Loading) 
Empirical Factor Composites 
Cancer-Specific 
Opportunity-Weighted  
Cancer-Specific Composites 
Fixed-Weighted (Simple Average)  
Cancer-Specific Composites 
Care-Modality-Specific 
Opportunity-Weighted  
Care-Modality-Specific 
Composites 
Fixed-Weighted (Simple Average) 
Care-Modality-Specific 
Composites 
 
 
Data Sources 
 Patient-level cancer registry and administrative data. We obtained data on patients who 
were diagnosed with cancer and/or received their first course of cancer therapy at a VA Medical 
Center (VAMC) during 2001-2004 from the VACCR.  The VACCR maintains information on 
patient demographics, tumor characteristics, and primary treatment for each incident cancer.  
Registry data were linked with additional data from 2000-2005, including VA administrative data 
(inpatient, outpatient, pharmacy, and laboratory data), Medicare administrative data (for 
Medicare-eligible veterans), and pain score data from office visits.  These data were also linked 
to the 2000 Census data to obtain zip code-level measures of socioeconomic status and the 
National Death Index to determine patient vital status through 2005. 
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We limited our analyses to veterans with colorectal, lung, or prostate cancer, the most 
prevalent cancers among veterans.  Of note, we excluded patients with hematological cancers 
from our analysis because a number of hospitals had no eligible hematological cancer patients 
for quality measures of interest and the average number of hematological patients per hospital 
was too small to suggest reliable hospital-level measure estimates and interpretable empirical 
factor analysis results.19,20  As described previously, we also excluded small numbers of patients 
whose cancers were reported based on autopsy or death certificate or for whom no reporting 
source was available, patients for whom data were incomplete (e.g., missing month of 
diagnosis, no administrative data between 45 days before diagnosis through 195 days after 
diagnosis), or patients with histologic features suggesting a primary cancer other than the 
cancer of interest.21   
Hospital exclusions.  Of the 128 VAMCs, 10 had no cancer patients and were excluded 
from our analysis. We then ranked the remaining 118 hospitals according to cancer patient 
volume.  Hospitals with cancer patient volume below the median accounted for relatively few or 
no patients across most quality measures of interest and were also excluded leaving 59 
hospitals accounting for roughly 70% of VA cancer patients.   
 
Cancer Care Quality Measures 
In total, we assessed 13 cancer-related process measures21,22 reflecting evidence-based 
nationally recommended guidelines for colorectal cancer, lung cancer, and prostate cancer care 
during the study period of 2001-2005.23-33 We computed unadjusted hospital-level rates of 
recommended cancer care and treatment by aggregating VA patient-level administrative 
process measure data for each hospital. 
Interunit reliability.  We computed the average interunit reliability (IUR) for each measure 
to determine how reliably each measure distinguished performance across the 59 hospitals.34  
The IURs ranged from 0.13 to 0.98 with most measures (8 out of 13) exhibiting an average   
 40 
 
IUR ≥ 0.50.  We also considered an additional measure, adjuvant chemotherapy for stage III 
colon cancer; however the IUR for this measure was less than 0.01, indicating that no variation 
in hospital performance could be determined.  We therefore excluded this measure from our 
analysis.   
A description of each measure, cohort eligibility, number of eligible patients, and each 
measure’s interunit reliability is provided in Table 2.2.
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Table 2.2 Hospital-Level Cancer Care Process Quality Measures (N=59 Hospitals) 
 
Quality Measure Definition Cohort Total # Patients 
Average 
Interunit 
Reliability 
     
Colorectal Cancer     
Early Stage (Stage I/II vs. 
III/IV) at Presentation, 
Colon Cancer
23
 
Patients diagnosed with stage I & II vs. 
stage III & IV colon cancer 
All patients with stage I-IV colon 
cancer. 
7316 .62 
Early Stage (Stage I/II vs. 
III/IV) at Presentation, 
Rectal Cancer
24
 
Patients diagnosed with stage I & II vs. 
stage III & IV rectal cancer 
All patients with stage I-IV rectal 
cancer. 
2047 .12 
Curative Surgery for 
Stage I, II, or III Colon 
Cancer
23
 
Proportion of patients with Stage I, II, or 
III colon cancer who underwent curative 
resection within 180 days of diagnosis; 
polypectomy/local excision of the tumor 
for stage 1 T1 tumors that have well- or 
moderately differentiated tumor grades 
were also included 
All stage I/II/III colon cancer patients.  
Patients had to be alive and not 
enrolled in a Medicare HMO through 
180 days from surgery. 
5009 .72 
Curative Surgery for 
Stage I, II, or III Rectal 
Cancer
24
 
Proportion of patients with Stage I, II, or 
III colon cancer who underwent curative 
resection within 180 days of diagnosis; 
polypectomy/local excision of the tumor 
for stage 1 T1 tumors that have well- or 
moderately differentiated tumor grades 
were also included 
All stage I/II/III rectal cancer patients.  
Patients had to be alive and not 
enrolled in a Medicare HMO through 
180 days from surgery. 
1495 .29 
Adjuvant Chemotherapy 
and Radiation Therapy for 
Stage II or III Rectal 
Cancer
24
 
Receipt of both adjuvant chemotherapy 
with 5-fluorouracil or capecitabine and 
radiation therapy before or within 140 
days following curative intent resection for 
stage II or III rectal cancer  
All stage II/III rectal cancer patients 
who underwent curative-intent 
resection.  Patients had to be alive 
and not enrolled in a Medicare HMO 
through 180 days from surgery. 
648 .32 
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Table 2.2 (Continued)     
     
Lung Cancer     
Curative Surgery for 
Stage I or II Non-Small 
Cell Lung Cancer
25
 
Pneumonectomy, lobectomy, or wedge or 
segmental resection within 180 days of 
diagnosis 
All stage I/II non-small cell lung 
cancer patients. Patients had to be 
alive and not enrolled in a Medicare 
HMO through 180 days from 
diagnosis. Patients were also 
included if they died within 180 days 
but underwent surgery. 
3564 .87 
Mediastinal Evaluation for 
Stage I or II Non-Small 
Cell Lung Cancer
25
 
Mediastinal evaluation from 45 days 
before diagnosis through the date of 
surgery 
All stage I/II non-small cell lung 
cancer patients who underwent 
lobectomy or pneumonectomy. 
Patients had to be alive and not 
enrolled in a Medicare HMO through 
180 days from surgery. 
1833 .68 
Chemotherapy and/or 
Radiation for Resected 
Stage IIIA Non-Small Cell 
Lung Cancer
25
 
Chemotherapy and/or radiation therapy 
from 30 days before diagnosis through 90 
days after date of surgery 
All stage IIIA non-small cell lung 
cancer patients who underwent 
lobectomy or pneumonectomy or 
wedge resection.  Patients had to be 
alive and not enrolled in a Medicare 
HMO through 90 days from surgery. 
311 .32 
Chemotherapy and 
Radiation for Limited-
Stage Small Cell Lung 
Cancer
26
 
Cisplatin or carboplatin and etoposide 
with concurrent radiation therapy within 
180 days of diagnosis; chemotherapy 
must start between the start and end 
dates of radiation therapy 
All limited-stage small cell lung cancer 
patients. Patients had to be alive 
through 45 days from diagnosis and 
not enrolled in a Medicare HMO 
through 180 days from diagnosis. 
854 .40 
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Table 2.2 (Continued)     
     
Prostate Cancer     
Androgen Ablation within 
120 Days for Men with 
Stage IV Prostate 
Cancer
28,29,31,32
 
Androgen deprivation therapy with a 
gonadotropin-releasing hormone (GnRH) 
agonist or bilateral orchiectomy within 
120 days of diagnosis 
All prostate cancer patients with stage 
IV cancer at diagnosis. Patients had 
to be alive and not enrolled in a 
Medicare HMO through 120 days 
from diagnosis. 
1281 .73 
Oral Anti-Androgen 
before Initiating 
Gonadotropin Releasing 
Hormone (GnRH) Agonist 
Therapy for Metastatic 
Prostate Cancer
27
 
Proportion of men with metastatic cancer 
who are started on GnRH agonist who 
also fill a prescription for an oral anti-
androgen for at least 2 weeks, beginning 
at least 1 week before first dose of GnRH 
agonist 
All prostate cancer patients with stage 
IV cancer at diagnosis who started a 
GnRH agonist. 
1192 .56 
Adjuvant Androgen 
Deprivation Therapy for 
High-Risk Cancers 
Treated with Radiation 
Therapy
27
 
Proportion of patients with high-risk 
prostate cancer (gleason 8-10 or PSA 
>20 or stage T3 or greater) treated with 
radiation who also receive hormonal 
therapy (adjuvant or neoadjuvant) 
All patients with high risk, non-
metastatic tumors treated with 
radiation therapy within 180 days of 
diagnosis. Patients were required to 
be alive and not enrolled in a 
Medicare HMO through 180 days 
from diagnosis. We only included 
cases in 2001-2002 because Gleason 
7 tumors could not be distinguished 
from Gleason 8 tumors in 2003-2004. 
3190 .86 
3-Dimensional Conformal 
Radiotherapy (3-D CRT)  
or Intensity-Modulated 
Radiation Therapy (IMRT) 
for Prostate Cancer 
Patients Treated with 
Electron Beam Radiation 
Therapy (XRT)
27,30,33
 
Receipt of 3D-CRT or IMRT among men 
with local or regional prostate cancer who 
received external beam radiation therapy 
within 180 days of diagnosis 
All patients with local or regional 
prostate cancer at diagnosis who also 
had evidence of external beam 
radiation therapy in administrative 
data.  Patients had to be alive and not 
enrolled in a Medicare HMO through 
180 days from diagnosis. 
6413 .98 
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 Cancer Survival  
 We determined patient vital status using the National Death Index, VA administrative 
data, and Medicare administrative data sources.   We computed time to death from any cause 
and censored patients alive as of December 31, 2005, the last date where we had complete 
vital status data available from all sources. 
 
Analysis 
Empirical factor composite measures.  We employed exploratory factor analyses to 
identify groups of highly correlated hospital-level cancer care process measures.  Because a 
small number of hospitals exhibited missing values on a few measures where they had no 
eligible patients, we imputed missing hospital-level process measure data using the SAS PROC 
MI procedure. We analyzed the completed covariance matrix obtained from the SAS PROC MI 
procedure using the SAS PROC FACTOR procedure with an oblique rotation (PROMAX) 
specification, which allowed for correlations among factors.18  We used a factor loading cutoff of 
.30 to make determinations about whether a factor loading was significant.  In cases where a 
measure exhibited factor loadings greater than or equal to .30 on multiple factor domains, we 
only accounted for the contribution of that measure on the factor domain where its factor loading 
was the highest (i.e., dominant factor loading).   
To compute fixed-weighted empirical factor composite scores for each of the empirical 
factor domains, we first standardized dominant factor loading weights within each factor domain 
so that they summed to 1.  We then multiplied each hospital’s cancer care process measure 
rate by its corresponding standardized factor loading weight and summed the weighted process 
measure scores within each factor domain.  To compute opportunity-weighted empirical factor 
composite scores, we first computed the number of patients eligible for each process measure 
(i.e., care opportunities) and summed by empirical factor domain groupings to create care 
opportunity denominators for each empirical factor domain.   We then computed and summed 
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the number of eligible patients that received recommended care for each empirical factor 
domain (i.e., care successes).  Finally, we divided each empirical factor domain care success 
numerator by its corresponding care opportunity denominator.   
Cancer-specific composite measures.  We generated two sets of colorectal cancer, lung 
cancer, and prostate cancer care composite measures using fixed- and opportunity-based 
weighting.  To compute fixed-weighted composite scores for each cancer type, we averaged 
process measure rates by cancer type. To compute opportunity-weighted cancer-specific 
composite scores, we employed the same opportunity based weighting methods described 
above.  In particular, we first computed the number of patients eligible for each cancer-specific 
process measure and summed by cancer type to create cancer-specific care opportunity 
denominators.  We then computed and summed the number of eligible patients that received 
recommended care by cancer type.  Lastly, we divided each cancer-specific care success 
numerator by its corresponding care opportunity denominator.   
 Care-modality-specific composite measures.  We also generated two sets of care-
modality-specific composite measures for (1) early screening and evaluation, (2) surgical 
treatment, and (3) non-surgical treatment using the same fixed- and opportunity-based 
weighting methods described above.   
 Each of the resulting composite measures, of any type, could range in value from 0 to 
1.0.  We used Pearson correlations to assess associations and distinctions among the individual 
composite measures. 
 
Modeling all-cause survival by cancer type.  We estimated Cox proportional hazard 
models predicting survival time for colon cancer, rectal cancer, non-small cell lung cancer, and 
small cell lung cancer (separate models for each cancer type) as a function of the composite 
scores generated in each of the six approaches (one cancer type survival model per composite 
measure scheme).  We did not model prostate cancer survival because the vast majority of 
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patients with prostate cancer are diagnosed with local or regional disease, for which the 5-year 
relative survival approaches 100%.35  We used robust “sandwich” estimators of variance to 
adjust for within-hospital clustering.  In all models, we adjusted for patient characteristics 
including age, race, sex, marital status, area-level socioeconomic status based on the zip code 
of the patient’s residence (the percentage of college graduates and the percentage of persons 
living below the poverty level), distance from the patients’ residence to the facility in which their 
cancer was reported, prior cancer history, comorbidities (measured using the Klabunde 
modification of the Charlson score36,37 separating chronic obstructive pulmonary disease 
[COPD] from the Charlson score for lung cancer patients), and tumor grade, stage, and size.  
We did not adjust for hospital characteristics because we were concerned that some hospital 
structural measures (e.g., onsite availability of specialized services and providers) might capture 
aspects of cancer care quality that may also be reflected in our composite measures.  For all 
models, we multiplied the parameter estimate associated with each composite measure by 2 
times the measure's standard deviation (SD), so that the reported hazard ratios reflect survival 
differences associated with a 2 SD improvement in performance on that measure.  Although this 
study was exploratory in nature, we also adjusted p-values for multiple comparisons using the 
Benjamini-Hochberg procedure.38,39 
 
Impact of opportunity- vs. fixed-weights on composite scores.  Compared with fixed-
weighting, opportunity-based weights reflect the mix of eligible patients for each quality measure 
(i.e., case mix), which can vary across provider units (e.g., physicians, hospitals).  This can be 
of concern if provider units differ in their case mix of eligible patients for "difficult to achieve" 
quality measures.  For example, suppose that opportunity-based composites measures were 
generated for Hospital 1 (N=100 patients) and Hospital 2 (N=100) based on two quality 
indicators, Measure A ("more difficult to achieve") and Measure B ("less difficult to achieve"), 
where overall performance for both hospitals on Measure A is 0.40 and Measure B is 0.90.  If 
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only 10 of the 100 patients at Hospital 1 are eligible for Measure A and the remaining 90 
patients are eligible for Measure B, while 50 of the 100 patients at Hospital 2 are eligible for 
Measure A and the remaining 50 patients are eligible for Measure B, then the opportunity-based 
composite scores for Hospital 1 and Hospital 2 would equal 0.85 and 0.65, respectively.  Thus, 
the opportunity-based composite scores for Hospitals 1 and 2 would reflect the relative mix of 
patients across hospitals and not necessarily true differences in care quality.  To assess the 
relative impact of opportunity- vs. fixed-weighting on hospital composite scores, we recomputed 
the six types of composite measures for each hospital, replacing each individual hospital’s 
performance measure rate with the overall mean of each performance measure. Thus, each set 
of recomputed fixed-weighted composite scores would be the same across all hospitals while 
the recomputed opportunity-based weighted composite scores could vary depending on the 
case mix of eligible patients at each hospital. 
 
All analyses were conducted using SAS 9.3.  
  
IV. RESULTS 
Table 2.3 presents patient-level descriptive data by cancer type.  On average, most VA 
cancer patients were over age 65, White non-Hispanic, male, married, and exhibited no prior 
history of cancer and a Charlson score of 0.  Table 2.4 displays unadjusted hospital-level cancer 
care process measure rates.
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Table 2.3 Patient Characteristics in Cancer Cohorts 
 
   
Colon Rectal 
Non-Small 
Cell Lung 
Small         
Cell Lung 
Prostate    
   N = 7,725 N = 2,233 N = 17,511 N = 2,875 N = 31,238 
        
        
Characteristics      
        
 Age - %      
  <60 yrs 20.3 28.4 23.6 25.0 22.4 
  60-64 yrs 12.4 12.7 14.1 16.6 16.3 
  65-69 yrs 14.0 13.0 15.9 15.4 20.2 
  ≥ 70 yrs 53.3 45.9 46.4 43.0 41.1 
        
 Race - %      
  White 71.3 76.4 76.1 82.3 62.2 
  Black 19.8 14.4 20.1 14.0 27.2 
  Hispanic 6.5 6.7 2.1 2.2 7.0 
  Other 2.5 2.5 1.7 1.6 3.7 
        
 Gender - %      
  Female 2.0 1.0 1.7 2.0  
  Male 98.0 99.0 98.3 98.0 100.0 
        
 Marital Status - %      
  Unmarried 39.4 40.2 53.0 51.1 45.1 
  Married 50.7 49.3 45.5 47.8 53.3 
  Unknown 9.9 10.6 1.6 1.1 1.7 
        
 Prior History of Cancer - %      
  No 85.8 87.1 82.0 84.4 93.1 
  Yes 14.2 13.0 18.0 15.7 7.0 
        
 Charlson Comorbidity Score - %      
  0 51.2 61.2 61.5 61.6 63.3 
  1 28.3 24.3 22.3 21.6 24.5 
  2 11.7 8.3 9.5 9.6 7.7 
  3 + 8.8 6.1 6.7 7.3 4.5 
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Table 2.3 (Continued) 
        
        
 Year of Diagnosis - %      
  2001 24.1 23.1 24.7 23.5 24.5 
  2002 25.6 24.3 24.8 24.8 25.3 
  2003 25.3 25.0 25.3 25.0 25.1 
  2004 25.0 27.6 25.2 26.7 25.1 
        
 Tumor Stage - %      
  Stage I (least advanced) 30.0 34.5 25.4  81.8
‡
 
  Stage II 25.3 24.0 7.1 36.1
†
  
  Stage III 21.6 18.9 26.7  7.8
‡
 
  Stage IV (most advanced) 18.4 16.2 37.7 60.2
†
 4.9
‡
 
  Stage Missing/Unknown 4.7 6.5 3.2             3.7                 5.6  
        
 % Population ≥ 65 Yrs Living Below Poverty in 
Zip Code of Residence - % 
 
 
   
  Q1 (0 - <7.9%) 23.8 24.4 23.8 25.3 23.7 
  Q2 (7.9 - <12.8%) 21.8 22.6 22.0 24.1 21.4 
  Q3 (12.8 - <19.5%) 23.0 23.1 23.6 22.7 23.0 
  Q4 (19.5 - 76.9%) 26.1 25.3 25.8 23.9 26.8 
  Missing/Unknown 5.4 4.7 4.8 5.0 5.1 
        
 % Population College Graduates in Zip Code of 
Residence - % 
     
  Q1 (<15.9%) 23.6 25.9 24.3 24.4 24.3 
  Q2 (15.9- <21.6%) 22.7 22.4 23.3 23.7 22.8 
  Q3 (21.6- <30.0%) 22.6 23.3 22.9 22.4 23.0 
  Q4 (30.0-100.0%) 25.8 23.7 24.7 24.5 24.8 
  Missing/Unknown 5.4 4.6 4.8 5.0 5.1 
        
 Average Distance to Reporting Hospital - Miles 50.6 50.9 58.0 56.5 49.6 
        
        
 † – Small cell lung cancer stage categories (in order from least advanced to most advanced): limited stage, extensive stage 
‡ – Prostate cancer stage categories (in order from least advanced to most advanced): local, regional, distant 
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Table 2.4 Unadjusted Hospital-Level Cancer Care Process Measure Rates (N= 59 Hospitals) 
 
Hospital-level Cancer Care Process Measures – Mean Hospital Rates (SD) 
 Colon Cancer   
 Early Stage (Stage I/II vs. III/IV) at Presentation, Colon Cancer 
 
55.3 (7.9) 
 Early Stage (Stage I/II vs. III/IV) at Presentation, Rectal Cancer 
 
58.1 (9.8) 
 Curative Surgery for Stage I, II, or III Colon Cancer 
 
 
 
93.9 (4.7) 
 Curative Surgery for Stage I, II, or III Rectal Cancer 
 
 
76.4 (17.3) 
 Adjuvant Chemotherapy and Radiation Therapy for Stage II or III 
Rectal Cancer 
 
75.8 (9.9) 
 Lung Cancer   
 Curative Surgery for Stage I or II Non-Small Cell Lung Cancer 
 
54.5 (19.2) 
 Mediastinal Evaluation for Stage I or II Non-Small Cell Lung Cancer 
 
88.5 (10.6) 
 Chemotherapy and/or Radiation for Resected Stage IIIA  
Non-Small Cell Lung Cancer 
 
69.6 (29.6) 
 Chemotherapy and Radiation for Limited-Stage  
Small Cell Lung Cancer 
 
59.7 (21.3) 
 
Prostate Cancer 
 
 Androgen Ablation within 120 Days for Men with Stage IV  
Prostate Cancer 
74.3 (18.4) 
 Oral Anti-Androgen before Initiating GnRH Agonist Therapy for 
Metastatic Prostate Cancer 
 
81.5 (13.5) 
 Adjuvant Androgen Deprivation Therapy for High-Risk Cancers 
Treated with Radiation Therapy 
 
56.5 (18.1) 
 3-D CRT or IMRT for Prostate Cancer Patients Treated with EBRT 
 
58.6 (28.5) 
   
 
PET – Positron Emission Tomography 
XRT – External Beam Radiation Therapy 
GnRH – Gonadotropin Releasing Hormone 
3-D CRT – 3-Dimensional Conformal Radiation Therapy 
IMRT – Intensity Modulated Radiation Therapy 
EBRT – External-Beam Radiation Therapy 
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Factor Analysis  
 A four-factor solution emerged as most interpretable and accounted for 52.2% of the 
total variation in the facility-level cancer care process measures (see Table 2.5).  The first 
factor, “colorectal early screening,” consisted of two measures: early stage at presentation for 
colon cancer and early stage at presentation for rectal cancer.  The second factor, “prostate 
cancer treatment,” included three measures: androgen ablation within 120 days for men with 
stage IV prostate cancer, adjuvant deprivation therapy for high-risk cancers treated with 
radiation therapy, and 3-dimensional conformal radiation therapy or intensity modulated 
radiation therapy (3-D CRT or IMRT)  for prostate cancer patients treated with external beam 
radiation therapy. 
The third factor, “surgical treatment and related care,” consisted of curative surgery for 
stage I, II, or III colon and rectal cancers, curative surgery for stage I or II non-small cell lung 
cancer, mediastinal evaluation for stage I or II non-small cell lung cancer, and adjuvant 
chemotherapy and radiation therapy for stage II or III rectal cancer.  The adjuvant rectal cancer 
therapy measure loaded negatively on this factor.  The fourth factor, “non-surgical treatment,” 
included four measures: chemotherapy and/or radiation for resected stage IIIA non-small cell 
lung cancer, chemotherapy and radiation for limited-stage small cell lung cancer, and oral anti-
androgen before initiating gonadotropin release hormone (GnRH) agonist therapy for metastatic 
prostate cancer. 
 
Correlations Within and Among Composite Measure Groupings 
The groupings for the cancer-specific and care-modality-specific composite measures 
are also included in Table 2.5. The measure groupings that emerged from the empirical factor 
analysis were consistently organized neither by cancer type nor by modality of care.  Instead, 
the factor domains included cancer-specific factors for "colorectal early screening" and "prostate 
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cancer treatment" and care-modality-specific factors for "surgical treatment and related care” 
and "non-surgical treatment.”
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Table 2.5 Cancer Care Composite Measure Grouping Results: Empirical Factor Domains, Cancer-Specific, and Care-Modality-Specific 
 
  Empirical Factor Analysis Cancer-Specific Care-Modality-Specific 
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  Factor 
Loading 
Factor 
Loading 
Factor 
Loading 
Factor 
Loading 
      
Quality Measure           
            
   Colon Cancer 
 
          
 Early Stage (Stage I/II vs. III/IV) 
at Presentation, Colon Cancer 
 
0.82
†
 
 
0.01 -0.09 -0.01  
 
   
 
  
 Early Stage (Stage I/II vs. III/IV) 
at Presentation, Rectal Cancer 
 
0.81
†
 
 
-0.27 -0.06 -0.01  
 
   
 
  
 Curative Surgery for Stage I, II, 
or III Colon Cancer 
 
0.04 0.02 0.72
†
 
 
0.05  
 
    
 
 
 Curative Surgery for Stage I, II, 
or III Rectal Cancer 
 
-0.25 -0.27 0.52
†
 
 
0.25  
 
    
 
 
 Adjuvant Chemotherapy and 
Radiation Therapy for Stage II or 
III Rectal Cancer 
 
0.04 -0.04 -0.44
†
 
 
0.11  
 
     
 
           
   Lung Cancer 
 
          
 Curative Surgery for Stage I or II 
Non-Small Cell Lung Cancer 
 
0.30 -0.11 0.44
†
 
 
-0.21   
 
   
 
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Table 2.5 (Continued)       
            
 Mediastinal Evaluation for Stage 
I or II Non-Small Cell Lung 
Cancer 
 
-0.09 0.09 0.46
†
 
 
-0.12   
 
  
 
  
 Chemotherapy and/or Radiation 
for Resected Stage IIIA Non-
Small Cell Lung Cancer 
 
0.24 0.06 -0.19 0.76
†
 
 
  
 
    
 
 Chemotherapy and Radiation for  
Limited-Stage Small Cell Lung 
Cancer 
 
-0.07 -0.14 0.12 0.62
†
 
 
  
 
    
 
   Prostate Cancer 
 
          
 Androgen Ablation within 120 
Days for Men with Stage IV 
Prostate Cancer 
 
-0.17 0.81
†
 
 
0.16 0.00    
 
   
 
 Oral Anti-Androgen before 
Initiating GnRH Agonist Therapy 
for Metastatic Prostate Cancer 
 
-0.14 0.05 -0.13 0.65
†
 
 
   
 
   
 
 Adjuvant Androgen Deprivation 
Therapy for High-Risk Cancers 
Treated with Radiation Therapy 
 
-0.10 0.78
†
 
 
-0.25 -0.05    
 
   
 
 3-D CRT or IMRT for Prostate 
Cancer Patients Treated with 
XRT 
 
0.48 0.54
†
 
 
0.36 0.11    
 
   
 
 
GnRH – Gonadotropin Releasing Hormone 
3-D CRT – 3-Dimensional Conformal Radiation Therapy 
IMRT – Intensity Modulated Radiation Therapy 
XRT – External-Beam Radiation Therapy 
† – Dominant factor loading with a value greater than or equal to .30 
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Compared with the empirically-derived "colorectal early screening" composite measure 
group, the cancer-specific "colorectal care" composite group consisted of a broader set of 
colorectal care measures reflecting early screening/diagnosis, curative surgery, and adjuvant 
therapy.  Correlations (r) between the empirically-derived "colorectal early screening" 
composites (fixed- and opportunity-weighted) and cancer-specific "colorectal care" composites 
were strong, ranging from r = 0.56 to 0.89, p<.0001 (see Table 2.6).  Correlations were also 
strong among the empirically-derived "colorectal early screening" composites and the care-
modality-specific "screening and evaluation" composites (r = 0.75 to 0.89; p<.0001), which 
consisted of the two colorectal early screening/diagnosis measures and mediastinal evaluation 
for early-stage non-small cell lung cancer.   
The empirically-derived "prostate cancer treatment" and cancer-specific "prostate care" 
composites were nearly identical in terms of measure composition and strongly correlated (r = 
0.86 to 0.99, p<.0001).  We also observed strong correlations among the empirically-derived 
"surgical treatment and related care" composites and the care-modality-specific "surgical 
treatment" composites, which strictly consisted of curative surgery measures (r = 0.61 to 0.96, 
p<.0001).  Compared with the empirically-derived "non-surgical treatment" composite measure 
group, the care-modality-specific "non-surgical treatment" composite measure group reflected a 
broader set of chemotherapy, radiation, and hormonal treatments.  Correlations between the 
empirically-derived "non-surgical treatment" composites and fixed-weighted care-modality-
specific "non-surgical treatment" composites ranged from r = 0.47 to 0.68, p<.0001; however, 
we observed no associations between the empirically-derived "non-surgical treatment" 
composites and the opportunity-weighted care-modality-specific "non-surgical treatment" 
composite, which primarily consisted of care opportunities for prostate hormonal treatments 
relative to other non-surgical treatments. 
We also observed correlations among several other composite measures that were 
largely driven by similarities in measure composition.  For example, the opportunity-weighted 
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cancer-specific "lung care" composite mostly consisted of lung surgery and surgery-related care 
opportunities and was strongly associated with the empirically-derived "surgical treatment and 
related care" composites (r = 0.68 to 0.70, p<.0001).   In addition, the care-modality-specific 
"non-surgical treatment" composites, which largely reflected prostate cancer measures, were 
strongly correlated with the empirically-derived "prostate cancer treatment" composites (r = 0.63 
to 0.98, p<.0001) and cancer-specific "prostate care" composites (r = 0.65 to 0.99, p<.0001).   
In general, correlations were strongest among composites with both similar measure 
compositions and weightings.  Although, compared with weighting scheme, grouping approach 
was the primary driver of correlations among most composites.  We did not observe correlations 
among similarly weighted composites that exhibited dissimilar measure compositions. 
Within each of the three composite measure groupings (empirical factor, cancer-specific, 
care-modality-specific), correlations for any given set of fixed- and opportunity-weighted 
composites were also strong, ranging from r = 0.51 to 0.95, p<.0001; however, we observed 
little to no correlation across the different domains of care.  For example, within the empirical 
factor grouping, the fixed- and opportunity-weighted "prostate cancer treatment" composites 
were strongly correlated (r = 0.86, p<.0001); although, neither of the "prostate cancer treatment" 
composites were associated with the empirical factor composites reflecting other domains of 
cancer care.
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Table 2.6 Pearson Correlations for Empirical Factor, Cancer-Specific, and Care-Modality-Specific Composites 
    
  FWEF OWEF 
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Colorectal Early Screening 1.00        
Prostate Treatment -0.04 1.00       
Surgical Treatment & Related Care 0.03 -0.01 1.00      
Non-Surgical Treatment 0.07 -0.03 -0.12 1.00     
O
W
E
F
 
Colorectal Early Screening 0.95*** 0.03 0.02 0.06 1.00    
Prostate Treatment 0.12 0.86*** 0.10 -0.01 0.17 1.00   
Surgical Treatment & Related Care 0.11 0.01 0.62*** -0.10 0.07 0.15 1.00  
Non-Surgical Treatment -0.07 -0.10 -0.02 0.80*** -0.08 -0.14 -0.02 1.00 
F
W
C
S
 Colorectal Care 0.58*** -0.08 -0.20 0.09 0.56*** 0.08 0.29* -0.02 
Lung Care 0.16 -0.02 0.31* 0.82*** 0.13 0.06 0.28* 0.60*** 
Prostate Care -0.01 0.95*** -0.01 0.13 0.05 0.88*** 0.00 0.08 
O
W
C
S
 Colorectal Care 0.84*** 0.08 0.18 0.04 0.89*** 0.26 0.29* -0.07 
Lung Care 0.24 -0.01 0.68*** 0.03 0.20 0.12 0.70*** 0.01 
Prostate Care 0.10 0.86*** 0.09 0.03 0.15 0.99*** 0.14 -0.08 
F
W
C
M
S
 
Screening & Evaluation 0.82*** 0.00 0.27* 0.00 0.75*** 0.13 0.22 -0.06 
Surgical Treatment 0.08 -0.05 0.81*** -0.10 0.08 0.11 0.75*** -0.07 
Non-Surgical Treatment 0.06 0.66*** -0.24 0.68*** 0.09 0.63*** -0.04 0.47*** 
O
W
C
M
S
 
Screening & Evaluation 0.87*** 0.05 0.30* -0.04 0.89*** 0.22 0.23 -0.17 
Surgical Treatment 0.07 -0.03 0.61*** -0.09 0.05 0.11 0.96*** 0.02 
Non-Surgical Treatment 0.11 0.84*** 0.06 0.08 0.16 0.98*** 0.14 -0.04 
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Table 2.6 (Continued) 
      
  FWCS OWCS FWMS OWMS 
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S
 Colorectal Care 1.00      
      
Lung Care 0.07 1.00     
      
Prostate Care -0.04 0.06 1.00    
      
O
W
C
S
 Colorectal Care 0.72*** 0.16 0.10 1.00   
      
Lung Care 0.09 0.51*** 0.00 0.27* 1.00  
      
Prostate Care 0.07 0.07 0.90*** 0.23 0.11 1.00       
F
W
C
M
S
 
Screening & Evaluation 0.41** 0.23 0.00 0.70*** 0.28* 0.09 1.00      
Surgical Treatment 0.18 0.31* -0.02 0.29* 0.82*** 0.11 0.08 1.00     
Non-Surgical Treatment 0.20 0.53*** 0.75*** 0.14 -0.01 0.65*** -0.01 -0.13 1.00    
O
W
C
M
S
 Screening & Evaluation 0.48** 0.22 0.05 0.86*** 0.49*** 0.18 0.80*** 0.34* 0.01 1.00   
Surgical Treatment 0.20 0.22 -0.02 0.25 0.61*** 0.11 0.09 0.75*** -0.09 0.13 1.00  
Non-Surgical Treatment 
0.11 0.12 0.88*** 0.24 0.12 0.99*** 0.09 0.11 0.69*** 0.19 0.10 1.00 
 
FWEF – Fixed Weighted Empirical Factor; OWEF – Opportunity Weighted Empirical Factor 
FWCS – Fixed Weighted Cancer-Specific; OWCS – Opportunity Weighted Cancer-Specific 
FWCMS – Fixed Weighted Care-Modality Specific; OWCMS – Opportunity Weighted Care-Modality-Specific 
* – Statistically significant at p<.05; ** – Statistically significant at p<.01; *** – Statistically significant at p<.001 
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Composite Measure Associations with Cancer Patient Survival  
Colon cancer.  In adjusted analyses, higher hospital performance on the fixed-weighted 
care-modality-specific "non-surgical treatment" composite was associated with better survival 
among colon cancer patients (adjusted hazard ratio (HR)=0.89 [0.82-0.97]; see Table 2.7).  No 
other composite measures were associated with colon cancer survival in adjusted analyses. 
Rectal cancer.  Several of the cancer-specific composites were associated with rectal 
cancer survival.  Higher performance on the fixed-weighted “colorectal care” composite and 
opportunity-weighted “colorectal care” composite were, respectively, associated with improved 
survival outcomes for rectal cancer patients (HR=0.80 [0.72-0.90]; HR=0.80 [0.70-0.91]).  
Interestingly, both the fixed- and opportunity-weighted “prostate care” composite measures were 
associated with worse survival outcomes for rectal cancer patients (HR=1.14 [1.02-1.28]; 
HR=1.18 [1.04-1.34]).  In addition, higher performance on the opportunity-weighted empirical 
factor "prostate cancer treatment" composite was also associated with lower rectal cancer 
survival (HR=1.16 [1.01-1.33]).  None of the care-modality-specific composites were associated 
with survival among rectal cancer patients. 
Non-small cell lung cancer.  Three composite measures were associated with non-small 
cell lung cancer survival.  Among the fixed-weighted empirical factor composite measures, 
higher performance on the “surgical treatment and related care” composite measure was 
associated with better survival for non-small cell lung cancer patients (HR=0.93 [0.88-0.98]).  
Survival was also better among non-small cell lung cancer patients treated at hospitals with 
higher performance on the opportunity-weighted cancer-specific “lung care” composite 
(HR=0.93 [0.88-0.99]), which due to the mix of lung cancer patients across hospitals, largely 
reflected care opportunities for lung cancer surgery and related care.  In addition, higher 
hospital performance on the fixed-weighted care-modality-specific “surgical treatment” 
composite was associated with better survival among non-small cell lung cancer patients 
(HR=0.94 [0.89-0.99]). 
 60 
 
Small cell lung cancer.  Only two composite measures were associated with survival for 
small cell lung cancer, a cancer for which surgical treatments do not have a role.  Both the fixed- 
and opportunity-weighted empirical factor "non-surgical treatment" composites were associated 
with better survival for small cell lung cancer patients (HR=0.93 [0.87-0.99]; HR=.91 [0.85-
0.98]).  None of the cancer-specific or care-modality specific composites were associated with 
survival among small cell lung cancer patients. 
In total, we observed 11 statistically significant associations between the composite 
measures and cancer patient survival.  After adjusting for multiple comparisons using the 
Benjamini-Hochberg procedure, only 2 of the 11 associations remained statistically significant; 
both the fixed- and opportunity-weighted "colorectal care" composites remained associated with 
better rectal cancer survival.
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Table 2.7 Adjusted Hazard of Cancer Death According to Hospital Cancer Care Composite Quality Scores: Comparison of                
Fixed- and Opportunity- Weighted Empirical Factor, Cancer-Specific, and Care-Modality-Specific Composites 
   
Colon Cancer 
N = 7,308 
Rectal Cancer 
N = 2,082 
Non-Small Cell 
Lung Cancer 
N = 17,380 
Small Cell 
Lung Cancer 
N = 2,831 
   
   
   HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
       
Hospital Composite Quality Measures     
       
 Fixed-Weighted Empirical Factor     
  Colorectal Early Screening 1.01(0.93-1.11) 0.94(0.81-1.09) 1.04(0.99-1.10) 0.94(0.87-1.01) 
  Prostate Treatment 0.94(0.86-1.03) 1.10(0.96-1.26) 0.96(0.91-1.02) 0.96(0.90-1.03) 
  Surgical Treatment and Related Care 1.02(0.94-1.11) 1.00(0.83-1.20) 0.93(0.88-0.98)** 0.98(0.92-1.05) 
  Non-Surgical Treatment 0.92(0.85-1.01) 0.99(0.90-1.09) 1.02(0.96-1.08) 0.93(0.87-0.99)* 
      
 Opportunity-Weighted Empirical Factor     
  Colorectal Early Screening 1.01(0.93-1.09) 0.90(0.77-1.06) 1.04(0.98-1.10) 0.93(0.86-1.01) 
  Prostate Treatment 0.93(0.85-1.02) 1.16(1.01-1.33)* 0.99(0.93-1.05) 0.98(0.91-1.06) 
  Surgical Treatment and Related Care 1.00(0.91-1.10) 0.90(0.80-1.02) 0.96(0.91-1.01) 0.98(0.93-1.04) 
  Non-Surgical Treatment 0.93(0.84-1.02) 1.04(0.92-1.17) 1.00(0.94-1.06) 0.91(0.85-0.98)* 
       
 Fixed-Weighted Cancer-Specific     
  Colorectal Care 0.97(0.89-1.05) 0.80(0.72-0.90)***
†
 1.03(0.97-1.09) 0.98(0.92-1.04) 
  Lung Care 0.92(0.85-0.99) 0.97(0.88-1.06) 0.97(0.92-1.03) 0.94(0.88-1.01) 
  Prostate Care 0.95(0.87-1.03) 1.14(1.02-1.28)* 0.98(0.93-1.03) 0.96(0.89-1.02) 
      
 Opportunity-Weighted Cancer-Specific     
  Colorectal Care 1.01(0.93-1.09) 0.80(0.70-0.91)**
†
 1.04(0.98-1.12) 0.95(0.87-1.03) 
  Lung Care 0.96(0.86-1.06) 1.04(0.90-1.21) 0.93(0.88-0.99)* 0.98(0.91-1.07) 
  Prostate Care 0.94(0.86-1.03) 1.18(1.04-1.34)* 0.99(0.94-1.05) 0.99(0.91-1.06) 
       
 Fixed-Weighted Care-Modality-Specific     
  Screening and Evaluation 1.00(0.91-1.10) 0.89(0.76-1.05) 1.00(0.95-1.06) 0.94(0.87-1.01) 
  Surgical Treatment 0.99(0.90-1.09) 0.96(0.83-1.10) 0.94(0.89-0.99)* 1.00(0.94-1.06) 
  Non-Surgical Treatment 0.89(0.82-0.97)** 1.02(0.93-1.11) 1.00(0.94-1.06) 0.93(0.86-1.02) 
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Table 2.7 (Continued) 
       
 Opportunity-Weighted Care-Modality-Specific     
  Screening and Evaluation 1.01(0.92-1.10) 0.92(0.79-1.08) 1.00(0.94-1.06) 0.96(0.89-1.03) 
  Surgical Treatment 1.02(0.93-1.11) 0.94(0.83-1.06) 0.97(0.92-1.03) 0.98(0.93-1.04) 
  Non-Surgical Treatment 0.92(0.84-1.01) 1.13(0.99-1.29) 1.00(0.95-1.06) 0.98(0.90-1.05) 
      
 
HR – All-cause adjusted Hazard Ratio reflecting survival differences associated with a 2 standard deviation (SD) improvement in 
performance on each composite measure 
Adjusted HRs obtained from Cox proportional hazard models with sandwich estimators to adjust for within-hospital clustering.  All 
models adjusted for patient characteristics including age, race, sex, marital status, area-level socioeconomic status based on the 
zip code of the patient’s residence (the percentage of college graduates, and the percentage of persons living below the poverty 
level), distance from the patients’ residence to the facility in which their cancer was reported, prior cancer history, comorbidities 
(measured using the Klabunde modification of the Charlson score with chronic obstructive pulmonary disease [COPD] examined 
separately from the Charlson score for lung cancer patients), and tumor grade, stage, size, and hospital characteristics including 
teaching hospital status, cancer patient volume, presence of cancer-specific tumor boards, and onsite availability of positron 
emission tomography and external radiation therapy. 
*    – Statistically significant at p<.05 
**  – Statistically significant at p<.01 
*** – Statistically significant at p<.001 
†   – Statistically significant after adjustment for multiple comparisons 
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Impact of Opportunity- vs. Fixed-Weighting on Composite Scores 
Table 2.8 summarizes data for the recomputed (calculated at the overall mean of each 
measure) fixed- and opportunity-weighted composite measures.  As expected, computing the 
fixed-weighted composite measures using the overall mean of each performance measure 
resulted in identical fixed-weighted composite scores across all hospitals.  Compared with the 
recomputed fixed-weighted composites, the recomputed opportunity-weighted composite scores 
varied extensively across hospitals.  For example, all hospitals exhibited a score of 0.83 on the 
recomputed fixed-weighted empirical factor "surgical treatment and related care" composite; 
however, scores on the recomputed opportunity-weighted "surgical treatment and related care" 
composite ranged from 0.75 to 0.87.  Thus, differences in the case mix of eligible patients 
across hospitals was an additional source of variation in the opportunity-weighted composite 
scores.
  
 
6
4
 
Table 2.8 Summary of Recomputed Fixed- and Opportunity-Weighted Empirical Factor, Cancer-Specific, and Care-Modality-Specific 
Composite Scores Calculated at the Mean of Each Quality Measure: Comparing Impact of Opportunity- vs. Fixed-Weighting 
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Score                     
Min 0.57 0.56 0.66 0.57 0.83 0.75 0.69 0.67 0.72 0.67 0.70 0.62 0.67 0.57 0.68 0.56 0.76 0.72 0.68 0.58 
Max 0.57 0.56 0.66 0.65 0.83 0.87 0.69 0.80 0.72 0.72 0.70 0.71 0.67 0.70 0.68 0.68 0.76 0.88 0.68 0.69 
SD 0.00 0.00 0.00 0.02 0.00 0.02 0.00 0.03 0.00 0.01 0.00 0.02 0.00 0.02 0.00 0.03 0.00 0.04 0.00 0.02 
 
OBS – Opportunity-Based Scoring Weight 
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V.  DISCUSSION 
In this study we compared multiple approaches for grouping and weighting individual 
hospital-level cancer-related quality indicators into composite measures of cancer care quality.  
Compared with cancer-specific and care-modality-specific composite measure groupings, the 
empirically-derived grouping approach reflected the natural relationships among cancer-related 
quality indicators.  These empirically-derived cancer care dimensions reflected a combination of 
cancer-specific and care-modality-specific process measure groupings and indicate that 
relationships among cancer care processes in the hospital setting may cross traditional 
boundaries of condition- or treatment-specific care delivery. 
In general, the factor-based measure groupings closely resembled many of the cancer-
specific and care-modality-specific measure groupings.  For example, the empirically-derived 
"prostate cancer treatment" and cancer-specific "prostate care" composites were strongly 
associated and comprised of nearly the same set of treatment measures, suggesting that 
prostate cancer treatment processes are a unique dimension of cancer care. This is consistent 
with the fact that prostate cancer care is often delivered by urologists, who are not oncologists 
and do not take care of other types of cancer patients. The empirical factor "colorectal early 
screening" composite and cancer-specific "colorectal care" composite were also strongly 
associated; although, the cancer-specific "colorectal care" group consisted of a broader set of 
colorectal screening and treatment measures.  In addition, the empirical factor "surgical 
treatment and related care" composites and "non-surgical treatment” composites were, 
respectively, associated with the care-modality-specific "surgical treatment" and "non-surgical 
treatment" composites.  Thus, surgical and non-surgical treatment emerged as important 
dimensions of cancer care.  We did not observe associations among different care domains 
within each of the three composite measure groupings (empirical factor, cancer-specific, care-
modality-specific), suggesting that each care domain may reflect a distinct dimension of care.  
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Despite differences in the methods used to generate the composite measures, patterns 
in predicting patient survival were generally similar, particularly for composites with similar 
measure compositions.  For example, although neither of the "colorectal early screening" 
empirical factor composites were associated with survival among colon or rectal cancer 
patients, both the fixed- and opportunity-weighted cancer-specific "colorectal care" composite 
measures were similarly associated with improved rectal cancer survival.  These findings 
suggest that a combination of care processes along the colorectal cancer care continuum (e.g., 
screening, surgery, chemotherapy) may be collectively important to rectal cancer care quality 
and survival outcomes.  We also observed nearly identical associations between both the 
empirical factor and care-modality-specific fixed-weighted surgical treatment composites and 
non-small cell lung cancer survival.  In addition, the opportunity-weighted cancer-specific “lung 
care” composite, which mostly reflected lung cancer surgery cases, was similarly associated 
with improved survival for non-small cell lung cancer.  These findings suggest that surgical 
treatment is an important dimension of non-small cell lung cancer care quality.  Unlike non-small 
cell lung cancer, surgical treatment is not indicated as a recommended course of treatment for 
small cell lung cancer.  We found that both the fixed- and opportunity-weighted empirical factor 
“non-surgical treatment” composites were positively associated with survival for small cell lung 
cancer.  Of note, neither of the care-modality-specific “non-surgical treatment” composites, 
which contained a broader set of less related non-surgical quality indicators, were associated 
with small cell lung cancer survival.  
Each of the composite methods explored in this study has strengths and weaknesses.  
Empirically-derived factor groupings reflect the underlying associations among cancer care 
processes and can identify important dimensions of cancer care quality and delivery.  Still, 
factor interpretability and plausibility can be a major challenge with this approach, particularly 
when the factor domains and empirical relationships among measures lack face validity.  
Cancer- and care-modality-specific composite groupings may be more immediately face-valid to 
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clinicians.  However, because cancer care quality and delivery may reflect a combination of 
cancer-specific and care-modality-specific care dimensions, use of simple condition- or 
treatment-specific grouping approaches may not be entirely sufficient. 
Simple averaging is often easier to implement and interpret than factor loading weights; 
however, this approach entails applying equal weights across quality indicators and hence 
implicitly suggests that each indicator is equally important to a particular dimension or 
composite measure of quality.  Empirical factor loading weights reflect both the relationships 
among quality indicators and the relative importance of each quality indicator to its underlying 
quality dimension.  However, the interpretation and plausibility of factor loadings weights  can be 
a challenge with this approach (e.g., negative factor loading for the adjuvant rectal cancer 
therapy measure).   
Opportunity-based weighting, on the other hand, is a relatively simple and commonly 
used approach for generating composites;3,6,13,17 however, this approach also presents some 
challenges to quality measurement.  Although we observed strong associations within each set 
of fixed- and opportunity-weighted composites, additional analyses revealed that opportunity-
based weights, due to differences in hospital case mix of eligible patients, are a source of 
chance variation (i.e., noise) in composite score calculations.  Thus, users of opportunity-based 
scoring methods should consider and assess the potential impact of case mix differences on 
opportunity-based composite scores. 
This exploratory study did not identify an optimal approach for grouping and weighting 
quality indicators into cancer care composites.  However, understanding the goals of potential 
users of cancer care quality data can also help inform the process for developing and reporting 
cancer care composite measures and ensure acceptance and use among stakeholders.  For 
example, health care providers (e.g., physicians, hospitals) are more likely to be interested in 
composite measures that can help stimulate and direct quality improvement efforts.40,41  Cancer 
patients in search of a health care provider may be especially interested in composite measures 
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that summarize care quality, survival, and patient-reported outcomes by cancer type.  And in an 
effort to steer patients toward cancer care providers that deliver cost-efficient and high quality 
care, insurers may favor composite measures that give weight to both costs and quality.  In 
addition, recent qualitative work that examined multistakeholder perspectives (i.e., consumers, 
payers, providers, purchasers) on composite measure use and development in ambulatory care 
revealed that most stakeholders preferred composite measures that were disease-specific and 
constructed using simple and transparent methods.40  Thus, understanding and balancing 
perspectives from various stakeholders during the measure development process remains an 
important issue. 
 
Limitations 
  To our knowledge, no previous study has examined approaches for generating 
composite measures of cancer care quality.  Our study’s strengths include our use of a broad 
set of cancer care process measures that reflect cancer care quality for three common types of 
cancer.   We also employed and compared a range of grouping and weighting approaches for 
generating cancer care composites. 
Our study’s limitations highlight some common challenges in quality measurement 
including the difficulty of measuring care quality for low-volume hospitals.  In this study, we 
excluded hospitals with very few cancer patients due to measure reliability concerns.  Thus, our 
findings may not generalize to hospitals with lower cancer patient volume.  We also did not risk 
adjust the hospital-level quality indicators used to compute our composite measures; although, 
in this first-step exploratory study, we were most interested in comparing methods for grouping 
and weighting measures into cancer care composite measures.  We did, however, adjust for 
patient clinical and demographic characteristics in our survival models.  In addition, we were 
unable to assess associations between our composite measures and other important outcomes 
of cancer care such as treatment toxicity, quality of life, and patient satisfaction.  Furthermore, to 
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our surprise, we observed negative associations between a few of our prostate cancer 
composite measures and rectal cancer survival.  Additional research is needed to better 
understand the nature of this relationship and/or whether these associations are spurious in 
nature. 
 
Conclusion 
Compared with individual quality indicators, cancer care composite measures may be 
better suited for capturing the most salient dimensions of cancer care and summarizing quality 
performance across hospitals.  However, these care dimensions and hospital performance 
scores can often vary depending on the methods used to generate composite measures; thus, 
use of transparent methods and consideration of stakeholders' (e.g., patients, providers, 
insurers) needs and objectives should be integrated into the composite measure development 
process. 
  
 70 
 
REFERENCES 
1. Staiger DO, Dimick JB, Baser O, Fan Z, Birkmeyer JD. Empirically derived composite 
measures of surgical performance. Med Care. 2009;47(2):226-233. 
2. Kroch E, Van Dusen C. Centers for Medicare and Medicaid Services (CMS)/Premier 
Hospital Quality Incentive Demonstration Project. 2012. Available at: 
https://www.premierinc.com/quality-safety/tools-services/p4p/hqi/downloads/premier-hqid-final-
white-paper-28nov2012.pdf. Accessed August 8, 2013. 
3. Lovett KM, Liang BA. Quality care opportunities: refining physician performance 
measurement in ambulatory care. Am J Manag Care. 2012;18(6):e212-216. 
4. Solberg LI, Crain AL, Tillema J, Scholle SH, Fontaine P, Whitebird R. Medical home 
transformation: a gradual process and a continuum of attainment. Ann Fam Med. 2013;11 Suppl 
1:S108-114. 
5. Minnesota HealthScores. Ratings by Condition. 2013. Available at: 
http://mnhealthscores.org/index.php?p=our_reports&sf=clinic&category_section=category_cond
ition&category=23. Accessed September 27, 2013. 
6. Glickman SW, Boulding W, Roos JM, Staelin R, Peterson ED, Schulman KA. Alternative 
pay-for-performance scoring methods: implications for quality improvement and patient 
outcomes. Med Care. 2009;47(10):1062-1068. 
7. Institute of Medicine. Ensuring Quality Cancer Care: National Academy Press; 1999. 
8. Centers for Medicare and Medicaid Services. PPS-Exempt Cancer Hospital Quality 
Reporting Listening Session. 2013. Available at: http://www.cms.gov/Medicare/Quality-
Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/HospitalHighlights.html. 
Accessed September 27, 2013. 
9. American College of Surgeons. CoC Quality of Care Measures. 2011. Available at: 
http://www.facs.org/cancer/qualitymeasures.html. Accessed September 27, 2013. 
10. National Quality Forum. NQF Endorses Cancer Measures. 2012. Available at: 
https://www.qualityforum.org/News_And_Resources/Press_Releases/2012/NQF_Endorses_Ca
ncer_Measures.aspx. Accessed September 27, 2013. 
11. Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of 
cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers 
Prev. 2003;12(1):4-13. 
12. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: 
systematic review and meta-analysis. Prev Med. 2007;45(2-3):93-106. 
13. Peterson ED, Delong ER, Masoudi FA, et al. ACCF/AHA 2010 position statement on 
composite measures for healthcare performance assessment: a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Performance Measures 
(writing Committee to develop a position statement on composite measures). Circulation. 
2010;121(15):1780-1791. 
 71 
 
14. Shwartz M, Pekoz EA, Christiansen CL, Burgess JF, Jr., Berlowitz D. Shrinkage 
estimators for a composite measure of quality conceptualized as a formative construct. Health 
Serv Res. 2013;48(1):271-289. 
15. Couralet M, Guerin S, Le Vaillant M, Loirat P, Minvielle E. Constructing a composite 
quality score for the care of acute myocardial infarction patients at discharge: impact on hospital 
ranking. Med Care. 2011;49(6):569-576. 
16. Jacobs R, Goddard M. How do performance indicators add up? An examination of 
composite indicators in public services. Public Money Manage. 2010;27(2):103-110. 
17. Centers for Medicare and Medicaid Services. A Blueprint for the CMS Measures 
Management System. 2012. Available at: http://www.cms.gov/Medicare/Quality-Initiatives-
Patient-Assessment-Instruments/MMS/Downloads/BlueprintVolume1-combined-v92.pdf. 
Accessed August 8, 2013. 
18. Zaslavsky AM, Shaul JA, Zaborski LB, Cioffi MJ, Cleary PD. Combining health plan 
performance indicators into simpler composite measures. Health Care Financ Rev. 
2002;23(4):101-115. 
19. Suhr D. Reliability, Exploratory & Confirmatory Factor Analysis for the Scale of Athletic 
Priorities. 2009. Available at: http://www2.sas.com/proceedings/sugi28/274-28.pdf. Accessed 
October 3, 2013. 
20. Child D. The Essentials of Factor Analysis. 3rd ed: Bloomsbury Academic; 2006. 
21. Keating NL, Landrum MB, Lamont EB, et al. Quality of care for older patients with cancer 
in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 
2011;154(11):727-736. 
22. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor 
boards and the quality of cancer care. J Natl Cancer Inst. 2013;105(2):113-121. 
23. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. 
Colon Cancer. Version 1.2001. Fort Washington, PA: NCCN; 2001. Available at: 
www.nccn.org/professionals/physician_gls/f_gudelines.asp. Accessed April 2, 2013. 
24. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. 
Rectal Cancer. Version 1.2001. Fort Washington, PA: NCCN; 2001. Available at: 
www.nccn.org/professionals/physician_gls/f_gudelines.asp. Accessed April 2, 2013. 
25. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. 
Lung Cancer. Version 1.2001. Fort Washington, PA: NCCN; 2001. Available at: 
www.nccn.org/professionals/physician_gls/f_gudelines.asp. Accessed April 2, 2013. 
26. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK. Practice guideline for the 
role of combination chemotherapy in the initial management of limited-stage small-cell lung 
cancer. Lung Cancer. 2004;43(2):223-240. 
 72 
 
27. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. 
Prostate Cancer. Version 1.2001. Fort Washington, PA: NCCN; 2001. Available at: 
www.nccn.org/professionals/physician_gls/f_gudelines.asp. Accessed April 2, 2013. 
28. The Medical Research Council Prostate Cancer Working Party Investigators Group. 
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical 
Research Council Trial. Br J Urol. 1997;79(2):235-246. 
29. Bahnson RR, Hanks GE, Huben RP, et al. NCCN practice guidelines for prostate 
cancer. 2000;14(11A):111-119. 
30. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of 
conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 
1999;353(9149):267-272. 
31. Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of 
estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the 
prostate. Cancer Res. 1941;1:293-297. 
32. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of 
castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-233. 
33. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 
2006;355(15):1583-1591. 
34. Zaslavsky AM. Statistical issues in reporting quality data: small samples and casemix 
variation. Int J Qual Health Care. 2001;13(6):481-488. 
35. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010, 
National Cancer Institute. Bethesda, MD. Based on November 2012 SEER data submission, 
posted to the SEER web site, April 2013. Available at: http://seer.cancer.gov/csr/1975_2010/. 
Accessed October 29, 2013. 
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 
1987;40(5):373-383. 
37. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index 
using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267. 
38. Thissen D, Steinberg L, Kuang D. Quick and easy implementation of the Benjamini-
Hochberg procedure for controlling the false positive rate in multiple comparisons. J Educ 
Behav Stat. 2002;27(1):77-83. 
39. Williams VSL, Jones LV, Tukey JW. Controlling error in multiple comparisons, with 
examples from state-to-state differences in educational achievement. J Educ Behav Stat 
1999;24:42-69. 
40. Martsolf GR, Scanlon DP, Christianson JB. Multistakeholder perspectives on composite 
measures of ambulatory care quality: a qualitative descriptive study. Med Care Res Rev. 
2013;70(4):434-448. 
 73 
 
41. Nietert PJ, Wessell AM, Jenkins RG, Feifer C, Nemeth LS, Ornstein SM. Using a 
summary measure for multiple quality indicators in primary care: the Summary QUality InDex 
(SQUID). Implement Sci. 2007;2:11. 
 
 
74 
 
Chapter 3  
Area-Level Factors Associated with Electronic Health Record Adoption  
in the Regional Extension Center Program 
 
I. INTRODUCTION 
Research suggests that practices using electronic health record systems (EHR) systems 
experience several benefits including greater efficiency, enhanced care quality, and improved 
patient outcomes.1-4  Despite this evidence, adoption of EHRs has been slow in the US relative 
to other developed nations.5  Much of the literature on facilitators and barriers to EHR adoption 
has primarily focused on provider- and practice-level factors, with less attention given to 
potential system- and area-level factors associated with EHR adoption.   
Insights from the diffusion of innovation literature highlight the important role of 
contextual factors in the innovation diffusion process. For example, pre-existing inequalities in a 
given society are typically reflected in its pattern of innovation diffusion.6  Given the large federal 
investment in promoting EHR adoption in recent years, identifying the contextual factors that 
could promote or impede EHR adoption is an area of great policy relevance.   
In this study, I explore associations between area-level factors and the adoption of EHR 
systems in the context of the Regional Extension Center (REC) Program, a federally funded 
program consisting of 62 diverse organizations that specialize in providing technical assistance 
to primary care providers during the EHR adoption and meaningful use process.  To conduct 
this study, I use county-level Regional Extension Center Performance data from the Office of 
the National Coordinator (ONC) for Health Information Technology (IT) supplemented with data 
from other county-level data sources, such as the American Community Survey, Area Resource 
File, and the Federal Communications Commission’s Local Telephone Competition and 
Broadband Deployment database. 
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II. BACKGROUND 
Electronic Health Record Adoption in the US: Current State of Affairs 
The Institute of Medicine (IOM) has long supported use of EHRs and clinical decision 
support systems as tools for improving care quality and efficiency.1  However, evidence 
pertaining to the actual benefits of EHRs and other forms of health IT has been mixed.  Some 
earlier studies indicate that health IT use is associated with less efficient medication prescribing, 
increases in patient care errors (e.g., medication errors, procedure errors), and clinical workflow 
challenges.5,7-9  However, more recent work suggests that practices with well-implemented EHR 
systems benefit from greater efficiency, enhanced care quality, and improved patient 
outcomes.2-4  Still, rates of EHR adoption have been relatively low in the US.  In 2008, only 
16.9% of all non-federal office-based providers had adopted at least a basic EHR system (see 
Table 3.1 for descriptions of basic and comprehensive EHRs).10 By 2010, this number had 
increased to about 25% office-based providers, and by 2012, approximately 40% of office-
based providers reported having a basic EHR system in place.11  Several factors account for 
this trend of low EHR adoption in the US, including large financial barriers, physician attitudes 
and unwillingness to change practice patterns, lack of interoperability across EHR systems, and 
misaligned incentives.12,13
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Table 3.1 Basic versus Comprehensive Electronic Health Record Systems 
 
Required EHR Functionalities   
Basic EHR no 
Clinician Notes 
Basic EHR with 
Clinician Notes Comprehensive EHR 
             
             
Electronic Clinical Information           
 Patient demographics     x   x   x  
 Physician notes        x   x  
 Nursing assessments       x     
 Problem lists     x   x   x  
 Medication lists    x   x   x  
 Discharge summaries    x   x   x  
 Advance directives            
             
Computerized Provider Order Entry           
 Lab reports           x  
 Radiology tests           x  
 Medications    x   x   x  
 Consultation requests          x  
 Nursing orders          x  
             
Results Management           
 View lab reports    x   x   x  
 View radiology reports    x   x   x  
 View radiology images          x  
 View diagnostic test 
results 
   x   x   x  
 View diagnostic test 
images 
         x  
 View consultant report          x  
             
Decision Support           
 Clinical guidelines          x  
 Clinical reminders          x  
 Drug allergy results          x  
 Drug-drug interactions          x  
 Drug-lab interactions          x  
 Drug dosing support          x  
             
 
Source: Office of the National Coordinator for Health IT 
14
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Disparities in EHR Adoption 
Rates of EHR adoption are particularly low for providers based in small practices and 
those working in underserved areas and communities with high levels of unmet need.  In a 2009 
study on EHR adoption in US hospitals, Jha et al. found that hospitals serving a larger 
proportion of poor patients were less likely than other hospitals to adopt EHRs.15  These same 
hospitals also provided care to a higher proportion of Medicaid patients, elderly black patients, 
and elderly Hispanic patients.  Another study found that increases in unemployment rates and 
poverty rates were associated with lower rates of EHR adoption among providers.16 Des 
Roches et al. also found that providers based in rural areas, small practices, and non-teaching 
hospitals were less likely than other hospitals to adopt EHR systems.17  Providers in smaller 
practices and/or underserved areas share barriers similar to those faced by most other 
providers; however, given their smaller practice size and/or general lack of financial resources, 
financial barriers are particularly pronounced for this group of providers.  
 
HITECH and the REC Program 
In an effort to spur widespread adoption and meaningful usea of EHRs throughout the 
US, Congress passed the Health Information Technology for Economic and Clinical Health 
(HITECH) Act as part of the American Recovery and Reinvestment Act of 2009.18  Among its 
many provisions, HITECH called for the establishment of the Centers for Medicare and 
Medicaid Services (CMS) EHR Incentive Programs as well as the REC Program.  
CMS EHR Incentive Programs.  The Medicare and Medicaid EHR Incentive Programs 
provide incentive payments to eligible hospitals and non-hospital based health professionals 
                                                          
a “Meaningful Use” is an evolving concept consisting of three stages. Meaningful use 
determinations are based on whether the provider has adopted a certified EHR system and is 
using the EHR to achieve specific objectives.  See Appendix Table 4.3 for ONC’s full description 
of “Meaningful Use”. 
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that demonstrate meaningful use of certified EHR technologies.b, 19 Although hospitals are 
allowed to receive payment from both programs, non-hospital based health providers can only 
participate in one program.  To qualify as a “Medicaid eligible” provider for the Medicaid EHR 
Incentive Program, health professionals must demonstrate a Medicaid or “needy individual” 
patient volume of at least 30% (20% for pediatricians) in addition to meeting other credential 
criteria.18,20 Eligibility for the Medicare EHR Incentive Program depends on the type of Medicare 
program that is applicable to a health provider.  In the case of Medicare’s managed care 
program, Medicare Advantage, providers employed by (or contracted with) a Medicare 
Advantage Organization (MAO) must provide at least 80% of Medicare patient services to 
enrollees of their MAO to qualify as a “Medicare Advantage eligible” health professional.21  
There are no patient volume requirements for traditional fee-for-service (FFS) Medicare.18,22   
The Medicare and Medicaid versions of the program are similar in many respects; yet, 
there are some key differences between the two programs.  Compared to the Medicare version 
of the program, the Medicaid EHR Incentive Program offers a larger maximum incentive 
payment for individual providers ($63,750 vs. $44,000), captures a broader group of eligible 
providers (i.e., physicians, nurse practitioners, certified nurse mid-wives, dentists, and physician 
assistants), and stipulates less stringent requirements for receiving payment (e.g., in the first 
year, Medicaid providers can receive payment for adopting, implementing, or upgrading EHR 
systems, while Medicare providers must demonstrate meaningful use of an EHR to receive 
payment).23  In addition, HITECH includes language that financially penalizes "Medicare FFS 
eligible" health professionals who fail to demonstrate meaningful use of an EHR system by 
2015.  "Medicare FFS eligible" health professionals who fail to achieve meaningful use will face 
                                                          
b The designation of “certified EHR technology” is determined by an ONC-Authorized Testing 
and Certification Body (ONC-ATCB).  A complete list of ONC-ATCB certified EHRs appear on 
ONC’s Certified Health IT Product List (CHPL).  Certified EHRs are eligible for use in attestation 
in the Medicare and Medicaid EHR Incentive Programs. 
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1% reductions in Medicare reimbursement payments in 2015, 2% reductions in 2016, and 3% 
reductions in 2017.18 
REC Program.  The REC Program is administered by ONC and consists of 62 diverse 
non-profit organizations throughout the US that were selected though a grant application 
process (see Appendix Table 4.4 for a listing of all 62 RECs and service areas).  RECs promote 
EHR adoption and meaningful use among providers through the provision of technical 
assistance, dissemination of best practices for EHR implementation, and outreach and 
education on the availability of financial resources to support EHR adoption (e.g., CMS EHR 
Incentive Payment Program).  These services are offered at little to no cost.   
In most instances, an REC is assigned to an individual state; however, for some RECs, 
service area jurisdictions span multiple states and/or a collection of counties within a state.  
REC organizations vary widely in terms of their experience and areas of expertise. For example, 
a few RECs are extensions of quality improvement organizations that work closely with state 
Medicaid agencies, some RECs are based in medical schools and local universities, and a few 
are affiliated with regional health information exchange initiatives.  In addition to the range of 
organizations that make up the REC program, RECs may differ in the types of strategies they 
implement to engage and assist providers.   
The REC program uses three key milestones (or performance measures): Milestone 1 
(provider enrollment and engagement), Milestone 2 (provider adoption of a certified EHR 
technology), and Milestone 3 (meaningful use of the EHR system).  Although RECs are 
permitted to offer services to all providers within their regional jurisdiction, HITECH includes 
language that prioritizes a select group of providers referred to as priority primary care 
providers. Priority primary care providers are primary care providers (PCPs) working in the 
following settings: 
1. Individual and small group practices of ten or fewer professionals with prescriptive 
privileges 
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2. Public hospitals 
3. Critical access hospitals 
4. Community health centers 
5. Rural health clinics; and 
6. Other settings that predominantly serve uninsured, underinsured, and medically 
underserved populations 
 
Insights from the Diffusion of Innovation Literature 
 The diffusion of innovation literature characterizes factors associated with an 
innovation's diffusion, including attributes of the innovation, characteristics of innovators, the 
type of innovation process (e.g., diffusion encouraged via policy), the nature of communication 
channels (e.g., media, interpersonal networks), environmental context, and the extent and 
nature of change agent efforts.6,24  For the purposes of this study, I focus on the role of 
environmental context and change agents as potential sources of variation in EHR adoption 
within the REC program.  By environmental context, I am specifically referring to area-level 
facilitating (and inhibiting) factors, such as the availability of financial, human, and informational 
resources, the extent of infrastructure development, and the presence of incentives.  As 
mentioned earlier, providers practicing in areas and health care facilities with fewer available 
resources (e.g., low income areas, rural clinics) are less likely to invest in expensive innovations 
like EHR systems.12,16,25  The state of the local technological infrastructure (e.g., broadband 
access) is also important to the EHR diffusion process.  For example, limited broadband 
capability in a given area can create additional challenges to EHR use and health information 
exchange.26  Also, financial incentives, such as cost savings and the CMS EHR Incentive 
Payment Programs can stimulate interest in EHR adoption.  In addition, awareness and 
knowledge of the benefits of an innovation also serve as motivators for adoption.12,27,28   
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 Moreover, social context and system-level factors also matter when considering potential 
sources of health care disparities. For example, research indicates that investments in 
innovative medical technologies may result in better patient outcomes;25 however, racial/ethnic 
minorities generally have less access to “high technology” hospitals where care may be of a 
higher quality.29,30  Assuming that adoption and meaningful use of EHRs facilitate improvements 
in care delivery, then a "digital divide" in EHR adoption could exacerbate health care disparities 
affecting communities already at greatest risk for lower care quality and worse health outcomes.  
In Diffusion of Innovations, Rogers emphasized the importance of accounting for pre-existing 
inequalities in a society before an innovation is introduced, arguing that when a system's 
structure is already unequal, introduction of an innovation could lead to greater inequalities if the 
strategy for promoting innovation diffusion fails to target vulnerable groups.27,28  Thus, identifying 
the area-level factors that might account for lower rates of EHR adoption in specific geographic 
areas and provider groups is of great importance and deserves special policy attention. 
The diffusion of innovation literature also describes the influence of change agents in the 
innovation adoption process.27  Characteristics of the change agent such as their 
communication strategies, experience with the client population, and trustworthiness play a 
critical role in the client's adoption decision.  Previous studies exploring patterns of EHR 
adoption in the context of other change agent programs have typically focused on provider 
characteristics and individual needs with little attention to the area-level factors and change 
agent differences that might account for variations in EHR adoption.  In addition, these earlier 
studies examined EHR adoption patterns prior to HITECH implementation.31,32  More recently, 
one study assessed geographic variations in REC participation among PCPs and found that 
REC penetration was higher in underserved areas;33 however, this study focused on Milestone 
1 of the REC program and did not assess geographic differences in EHR adoption among REC-
enrolled  providers.  Thus, there exists a gap in our current knowledge about area-level factors 
associated with EHR adoption, specifically in the era of HITECH where initiatives like the CMS 
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EHR Incentive Program and change agents like the  REC Program are actively engaged in the 
EHR diffusion process.  Filling this knowledge gap would be helpful to policymakers seeking to 
maximize widespread uptake and use of EHR systems among health providers. 
 
Research Aims 
In this study, I examine associations between EHR adoption among REC-enrolled PCPs 
and a broad range of contextual factors, including county-level indicators of underservice, 
presence of EHR-related incentives, technological infrastructure and capability, and exposure 
and engagement with health IT.  I am particularly interested in geographic inequities in EHR 
adoption according to county-level racial composition, urban/rural status, or health resource 
need.  In addition, I assess whether differences across RECs explain any variations in county-
level EHR adoption. 
 
III. METHODS 
Overview 
I used hierarchical models to assess associations between county characteristics and 
county-level rates of EHR adoption among REC-enrolled PCPs.  I accounted for the following 
county characteristics in my analyses: 
a) “Underserved area” status and resource availability - metropolitan status, federally 
qualified health center (FQHC) presence, health professional shortage area (HPSA) 
status, minority concentration 
b) Potential eligibility for EHR adoption incentives - concentration of Medicaid enrollees,  
concentration of Medicare fee-for-service enrollees, concentration of Medicare 
Advantage enrollees 
c) Technological infrastructure and capacity - broadband internet service access 
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d) Exposure and engagement with health IT Initiatives - proximity to major academic 
teaching hospitals, proximity to other ONC HITECH grantees, REC 
penetration/enrollment 
I also computed the intraclass correlation to determine whether differences across RECs 
explained any variations in county-level EHR adoption. 
 
Data Sources 
  Data on REC enrollment and EHR adoption among REC-enrolled PCPs, as well as 
estimated counts of PCPs were obtained from ONC’s Health IT Dashboard website.34  Regional 
Extension Center performance data are organized at the county-level and include county-level 
estimates of the number of PCPs who have enrolled with an REC (Milestone 1), adopted an 
EHR (Milestone 2), and achieved meaningful use (Milestone 3).  These REC performance data 
are self-reported by each REC using customer relationship management software.  All RECs 
collect documentation of milestone achievements from each provider and retain records for 
program management and federal auditing purposes.35,36  Documentation of Milestone 1 (REC 
enrollment) consists of a signed technical assistance contract between each REC and individual 
provider.  Milestone 2 (EHR adoption) documentation consists of verification from the provider 
or provider representative that an EHR system has been implemented with quality reporting and 
electronic prescribing capabilities enabled.  To verify Milestone 2 achievement, providers or 
their representatives typically submit a copy of an electronic prescribing summary from their 
EHR system along with a signed affidavit indicating that an EHR system with enabled quality 
reporting and electronic prescribing capabilities has been implemented.   Milestone 3 
(meaningful use) is documented based on certification of meaningful use attestation from the 
Centers for Medicare and Medicaid Services (CMS).35,37 
Counts of PCPs within each county were computed by ONC using data from the 2011 
SK&A Office-based Providers Database (SK&A Information Services, Irvine, CA, 2012).  Within 
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the ONC Health IT Dashboard, PCPs are defined as physicians, physician assistants, and nurse 
practitioners with specialties of Family Practice, General Practice, Internal Medicine, Geriatrics, 
Obstetrics and Gynecology, Pediatrics, and Adolescent Medicine. 
Additional county-level data on metropolitan status, FQHC presence, primary care HPSA 
status, Medicaid enrollment, and Medicare enrollment were obtained from the 2011-2012 Area 
Resource File.  County population and racial composition data were obtained from the 2006-
2010 (5-year estimate) American Community Survey.  Information on 2011 county-level 
broadband availability was obtained from the Federal Communications Commission’s Local 
Telephone Competition and Broadband Deployment database.38  Addresses for major teaching 
hospitals and ONC HITECH grantees were obtained from the Council of Teaching Hospitals and 
Health Systems and ONC’s Health IT Data Dashboard, respectively. 
Cohort 
For this analysis, the REC provider cohort consisted of PCPs enrolled with a REC as of 
September 2012, excluding PCPs located in the US territories.  Counties with no PCPs were 
excluded.  The final cohort included 126,472 REC-enrolled PCPs spanning 2,721 counties and 
59 RECs. 
 
Measures  
Outcome measure 
The outcome measure examined in this study was the county-level rate of EHR adoption 
among REC-enrolled PCPs, expressed as percentages.   
 
Explanatory measures 
Underserved area status.  County-level indicators of underserved area status and low 
resource availability included metropolitan status (non-metropolitan [rural] vs. metropolitan 
[urban]), FQHC presence (at least 1 FQHC in county vs. none), HPSA status (whole county 
 85 
 
HPSA, population group HPSA, geographic area HPSA, or non-HPSA), and minority 
concentration (proportion of minorities within total county population).  
Potential eligibility for CMS EHR adoption incentives.  Because the impact of the 
Medicare and Medicaid EHR Incentive Programs and Medicare payment penalties is to some 
extent dependent on each provider’s payer mix, geographic variations in the concentration of 
Medicaid and Medicare enrollees are likely to be associated with EHR adoption patterns.  To 
account for the potential impact of geographic variations in provider eligibility for CMS EHR 
financial incentives on differences in EHR adoption across counties, county-level measures of 
Medicaid enrollee concentration (proportion of Medicaid enrollees within total county 
population), Medicare FFS enrollee concentration, and Medicare Advantage enrollee 
concentration were included in the analysis.  Medicare FFS and Medicare Advantage (i.e., 
Medicare managed care) enrollment were examined as separate variables in this analysis 
because past research indicates that managed care penetration in an area is positively 
associated with EHR adoption among health providers;16 thus, the association between 
Medicare enrollment and EHR adoption may differ depending on the concentration of each type 
of Medicare program within the county population. 
Technological infrastructure and capability.  County-level broadband internet technology 
infrastructure and capability was measured by the number of broadband connections per 1,000 
households. 
Exposure and engagement with health IT.  Health provider exposure and engagement 
with health IT varies geographically and may contribute to variations in EHR adoption.  For 
example, in addition to the REC program, ONC oversees other HITECH programs that promote 
health IT and EHR adoption in different geographic areas.  These ONC HITECH programs 
include the State Health Information Exchange Cooperative Agreement which is helping to build 
capacity for health information exchange within and between states, the Strategic Health IT 
Advanced Research Projects (SHARP) which support EHR adoption and meaningful use 
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through innovative research, Community College and University-Based Training Programs 
which are tasked with training a skillful health IT workforce, and the Beacon Communities which 
are leveraging health IT to improve healthcare delivery and quality.  Furthermore, past research 
indicates that teaching hospitals are more likely to adopt EHRs than non-teaching hospitals;17,39 
and as a result, teaching hospital presence may contribute to greater awareness and interest in 
EHRs among health providers within a given area.   
The level of health IT exposure and engagement within each county was represented by 
proximity to the nearest major academic teaching hospital, proximity to the nearest ONC 
HITECH program grantee, and the REC enrollment rate among all PCPs in the county.  
Distances were computed using the “Near” spatial analysis tool in ArcMap 10.140  and reflect the 
distance from the county centroid to the point of interest (e.g., nearest teaching hospital).   
To facilitate comparisons of EHR adoption across different sets of county characteristics, 
all explanatory measures were coded as dichotomous variables.  In the case of continuous 
measures reflecting population concentrations/rates (e.g., minority concentration), four 
dichotomous variables corresponding to quartile values for each measure were generated (e.g., 
Q1 – quartile group for counties with lowest concentrations; Q4 – quartile group for counties 
with highest concentrations). 
 
Analysis 
In descriptive analyses, mean county unadjusted EHR adoption rates were computed for 
each category of county characteristics (explanatory measures) and compared using one-way 
ANOVA tests.   
Within the REC program, each REC is assigned to a collection of counties within a 
specific state or group of states, making RECs a potential source of variation in this analysis.  
To account for the multilevel nature of the data, hierarchical models were employed.  To assess 
the proportion of the total variance in EHR adoption that is attributable to differences across 
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RECs, a hierarchical linear model with random intercepts for RECs, but no covariates (Model 1) 
was estimated followed by computation of the intraclass correlation. 
 
Model 1: Unadjusted Random Intercepts Model 
Equation 1:                  
Equation 2:               
Random Part (Level 2):              
   
Random Part (Level1):               
   
   County 
   REC 
Intraclass Correlation =  
   
 
   
     
  
   
     
   Total Variance in Outcome 
 
where     represents the intercept for REC j consisting of    (the mean intercept value) and     
(the REC-specific random effect),      represents the residual term for county i of REC j,    
  
represents the amount of variance in outcome     (i.e., county-level EHR adoption rate) that is 
attributable to REC-level differences, and    
  represents the amount of variance in outcome     
that is attributable to county-level differences.   
Next, to examine associations between county-level characteristics and county-level 
EHR adoption, fixed effect covariates for the county-level explanatory measures (i.e., 
metropolitan status, FQHC presence, HPSA status, concentration of minorities, Medicaid 
enrollees, Medicare FFS enrollees, and Medicare Advantage enrollees, broadband connections 
per 1,000 households, distance to nearest teaching hospital, distance to nearest ONC HITECH 
grantee, and REC enrollment rate among PCPs) were added to “Equation 1” of the unadjusted 
 88 
 
random intercepts model of EHR adoption.  This adjusted random intercepts model (Model 2) 
estimates associations between county-level characteristics and EHR adoption while allowing 
for random variation in intercepts at the REC-level. 
 
All analyses were conducted using SAS 9.3.41 
 
IV. RESULTS 
Descriptive analyses 
Table 3.2 presents descriptive data for the 2,721 counties included in this study.  About 
two-thirds of study-eligible counties were non-metropolitan, about one-half of counties were 
served by at least one FQHC, and the majority of counties were designated as a HPSA of some 
type.  On average (i.e., in the average county), about one-fifth of the population were minorities, 
one-fifth were enrolled in Medicaid, one-sixth were enrolled in Medicare FFS, and about 2.9% 
were enrolled in Medicare Advantage.  The majority of counties exhibited broadband capabilities 
in excess of 400 connections per 1000 households. On average, PCPs in each county were 
about 94.7 miles away from the nearest major teaching hospital and 70.5 miles away from the 
nearest ONC HITECH grantee.  The average REC enrollment rate among PCPs in each county 
was 53.3%. 
Table 3.3 presents unadjusted comparisons of county-level EHR adoption rates among 
REC-enrolled PCPs for each category of county-level characteristics.  On average, about 73.1% 
(IQR=42.1; SD=33.4) of the 126,472 study-eligible REC-enrolled PCPs have adopted an EHR 
system.  Metropolitan counties, counties with FQHC presence, non-HPSA counties, counties 
with lower Medicare FFS enrollment rates, and counties with higher Medicare Advantage 
enrollment rates had higher EHR adoption rates.  Moreover, counties located in closer proximity 
to major teaching hospitals and ONC HITECH grantees also exhibited higher EHR adoption 
rates among REC-enrolled PCPs.
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Table 3.2  Geographic and Population Characteristics of US Counties (excludes US Territories)  
      
    US Counties  
    (N =2,721)  
      
Characteristics    
     
 Underserved Area Status and Resource Availability     
 Metropolitan Status     
  Metropolitan (Urban)  37.8%  
  Non-Metropolitan (Rural)  62.2%  
     
 FQHC Presence     
  No FQHC in County  50.0%  
  At Least 1 FQHC in County  50.0%  
     
 HPSA Status     
  Non-HPSA   35.2%  
  Population Group HPSA  35.0%  
  Geographic Area HPSA    9.8%  
  Whole County HPSA   20.0%  
      
 Minority Concentration    
  Mean Proportion Minorities in Population  21.5%  
      
 Eligibility for  EHR Adoption Incentives     
 Medicaid Enrollment Concentration    
  Mean Proportion Medicaid Enrollees                  
in Population 
 20.4%  
      
 Medicare FFS Enrollment Concentration    
  Mean Proportion Medicare FFS Enrollees           
in Population 
 15.4%  
      
 Medicare Advantage Enrollment Concentration    
  Mean Proportion Medicare Advantage Enrollees 
in Population 
  2.9%  
      
 Technological Infrastructure and Capacity     
 Broadband Connections per 1000 Households    
   x≤ 200   7.0%  
  200< x ≤ 400  28.0%  
  400< x ≤ 600  41.9%  
   x >600  23.1%  
      
 Exposure and Engagement with Health IT    
 Distance to Nearest Major Teaching Hospital    
  Mean Distance in Miles     94.7  
      
 Distance to Nearest ONC HITECH Grantee    
  Mean Distance in Miles    70.5  
     
 REC Enrollment Rate    
  Mean Proportion of PCPs Enrolled with an REC     53.3%  
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Table 3.2 (Continued) 
 
FQHC – Federally Qualified Health Center 
HPSA – Health Professional Shortage Area 
EHR – Electronic Health Record 
FFS – Fee-for-Service 
ONC – Office of the National Coordinator for Health Information Technology 
HITECH – Health Information Technology for Economic and Clinical Health Act 
PCP – Primary Care Provider 
REC – Regional Extension Center 
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Table 3.3 Unadjusted County-Level EHR Adoption Rates among REC-Enrolled PCPs by 
Geographic and Population Characteristics of US Counties (excludes US Territories) 
      
    County-Level  
    EHR Adoption Rate p-value 
      
Mean County-Level EHR Adoption Rate   73.1%  
    
Characteristics     
     
 Underserved Area Status and Resource Availability     
 Metropolitan Status    .0001 
  Metropolitan (Urban)  76.2%  
  Non-Metropolitan (Rural)  71.2%  
      
 FQHC Presence   <.0001 
  No FQHC in County  69.1%  
  At Least 1 FQHC in County  77.1%  
      
 HPSA Status    <.0001 
  Non-HPSA   77.0%  
  Population Group HPSA  72.2%  
  Geographic Area HPSA  71.1%  
  Whole County HPSA  68.8%  
      
 Minority Concentration    .8440 
  Q1 (<6.0%)  72.8%  
  Q2 (6.0%-14.2%)  73.2%  
  Q3 (14.3%-32.6%)  74.0%  
  Q4 (32.7%-98.8%)  72.4%  
      
 Eligibility for EHR Adoption Incentives     
 Medicaid Enrollment Concentration   .1296 
  Q1 (<14.4%)  72.4%  
  Q2 (14.4%-19.3%)  71.2%  
  Q3 (19.4%-25.2%)  73.5%  
  Q4 (25.3%-62.9%)  75.3%  
      
 Medicare FFS Enrollment Concentration   .0008 
  Q1 (<12.1%)  74.2%  
  Q2 (12.1%-15.3%)  76.6%  
  Q3 (15.4%-18.3%)  72.1%  
  Q4 (18.4%-37.2%)  69.5%  
      
 Medicare Advantage Enrollment Concentration   .0015 
  Q1 (<1.3%)  69.3%  
  Q2 (1.3%-2.3%)  73.6%  
  Q3 (2.4%-4.0%)  73.1%  
  Q4 (4.1%-14.1%)  76.3%  
      
 Technological Infrastructure and Capacity     
 Broadband Connections per 1000 Households   .2033 
   x≤ 200  73.8%  
  200< x ≤ 400  71.9%  
  400< x ≤ 600  72.4%  
   x >600  75.5%  
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Table 3.3 (Continued) 
      
 Exposure and Engagement with Health IT     
 Distance to Nearest Major Teaching Hospital   <.0001 
  ≤30 miles  76.8%  
  31-60 miles  75.5%  
  61-90 miles  73.4%  
  >90 miles  68.3%  
      
 Distance to Nearest ONC HITECH Grantee   <.0001 
  ≤30 miles  77.4%  
  31-60 miles  73.8%  
  61-90 miles  74.8%  
  >90 miles  67.5%  
     
 REC Enrollment Rate   .6512 
  Q1 (<31.0%)  74.2%  
  Q2 (31.0%-50.0%)  72.5%  
  Q3 (50.1%-80.0%)  73.6%  
  Q4 (80.1%-100%)  72.1%  
      
 
Boldface values are statistically significant at the P<.05 level. 
EHR – Electronic Health Record 
PCP – Primary Care Provider 
FQHC – Federally Qualified Health Center  
HPSA – Health Professional Shortage Area 
FFS – Fee-for-Service 
ONC – Office of the National Coordinator for Health Information Technology 
HITECH – Health Information Technology for Economic and Clinical Health Act 
REC – Regional Extension Center 
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Hierarchical models  
Approximately 7% of the total variance in EHR adoption rates among REC-enrolled 
PCPs across counties was explained by differences at the REC level (see Table 3.4 for 
covariance parameter estimates for Model 1).  Compared with the 32.4 percentage point 
standard deviation in county-level EHR adoption rates within RECs (   ), the REC-level 
standard deviation in EHR adoption rates (   ) was approximately 8.7 percentage points.  Thus, 
RECs accounted for a modest amount of the total variation in county-level EHR adoption rates. 
 Underserved area status.  Table 3.4 also presents results from the adjusted hierarchical 
model (Model 2).  In this model, FQHC presence was associated with EHR adoption among 
REC-enrolled PCPs.  On average, EHR adoption rates among counties with FQHC presence 
were 7.2 percentage points (p<.0001) higher than EHR adoption rates in otherwise similar 
counties with no FQHC presence.  REC-enrolled PCPs based in HPSA counties of all types 
were less likely to adopt EHRs relative to REC-enrolled PCPs based in non-HPSA counties.  
Compared with non-HPSA counties, EHR adoption rates were, on average, 5.3 percentage 
points lower in population group HPSAs (p=.002),  6.3 percentage points lower in geographic 
area HPSAs (p=.007), and 9.4 percentage points lower in whole county HPSAs (p <.0001). 
Minority concentration was also associated with EHR adoption among REC-enrolled PCPs.  
Counties in the highest quartile of minority concentration (Q4) exhibited EHR adoption rates that 
were, on average, 6.8 percentage points (p=.008) lower than EHR adoption rates in counties 
with the lowest concentration of minorities (Q1).   
County-level metropolitan status was not associated with county-level EHR adoption 
among REC-enrolled PCPs in adjusted analyses.   
 Potential eligibility for EHR adoption incentives.  Concentration of Medicaid enrollees 
was associated with rates of EHR adoption among REC-enrolled PCPs.  Compared with 
counties with the lowest concentration of Medicaid enrollees (Q1), counties with the highest 
concentration of Medicaid enrollees (Q4) exhibited EHR adoption rates that were, on average, 
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5.8 percentage points (p=.02) higher.  In addition, county-level EHR adoption rates among 
REC-enrolled PCPs were also associated with Medicare Advantage enrollment concentration, 
with counties having the highest Medicare Advantage enrollment concentrations (Q4) exhibiting 
EHR adoption rates that were, on average, 4.7 percentage points higher (p = .03) than EHR 
adoption rates among counties with the lowest concentration of Medicare Advantage enrollment 
(Q1).  
County-level Medicare FFS enrollment was negatively associated with EHR adoption in 
unadjusted comparisons, but not in adjusted analyses. 
 Technological infrastructure and capability.  County-level broadband internet access was 
not associated with county-level EHR adoption among REC-enrolled PCPs in adjusted 
analyses. 
 Exposure and engagement with health IT.  Distance to the nearest major teaching 
hospital, distance to the nearest ONC HITECH grantee, and rates of REC enrollment and were 
not associated with EHR adoption among REC-enrolled PCPs in adjusted analyses.
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Table 3.4 Random Intercepts Models Estimating County-Level EHR Adoption among  
REC-Enrolled PCPs 
      
   Unadjusted 
Model 1 
Adjusted 
Model 2 
   β (SE) β (SE) 
    
 Intercept 73.06 (1.40) 73.26 (4.85) 
   
 Underserved Area Status and Resource Availability   
 Metropolitan Status    
  Non-Metropolitan (Rural)  Reference 
  Metropolitan (Urban)  0.62 (1.74) 
    
 FQHC Presence   
  No FQHC in County  Reference 
  At Least 1 FQHC in County  7.21 (1.42) 
    
 HPSA Status    
  Non-HPSA   Reference 
  Population Group HPSA  -5.26 (1.67) 
  Geographic Area HPSA  -6.26 (2.33) 
  Whole County HPSA  -9.44 (1.97) 
     
 Minority Concentration    
  Q1 (<6.0%)  Reference 
  Q2 (6.0%-14.2%)  -1.02 (1.86) 
  Q3 (14.3%-32.6%)  -1.71 (2.16) 
  Q4 (32.7%-98.8%)  -6.83 (2.59) 
     
 Eligibility for EHR Adoption Incentives   
 Medicaid Enrollment Concentration   
  Q1 (<14.4%)  Reference 
  Q2 (14.4%-19.3%)  -1.68 (1.89) 
  Q3 (19.4%-25.2%)   0.22 (2.16) 
  Q4 (25.3%-62.9%)   5.81 (2.55) 
     
 Medicare FFS Enrollment Concentration   
  Q1 (<12.1%)  Reference 
  Q2 (12.1%-15.3%)   1.42 (1.91) 
  Q3 (15.4%-18.3%)  -3.12 (2.17) 
  Q4 (18.4%-37.2%)  -3.61 (2.38) 
     
 Medicare Advantage Enrollment Concentration   
  Q1 (<1.3%)  Reference 
  Q2 (1.3%-2.3%)   1.77 (1.86) 
  Q3 (2.4%-4.0%)   1.28 (1.98) 
  Q4 (4.1%-14.1%)   4.65 (2.20) 
     
 Technological Infrastructure and Capacity   
 Broadband Connections per 1000 Households   
   x≤ 200  Reference 
  200< x ≤ 400  -1.47 (2.70) 
  400< x ≤ 600  -0.02 (2.79) 
   x >600   1.35 (3.20) 
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Table 3.4 (Continued) 
   
 Exposure and Engagement with Health IT   
 Distance to Nearest Major Teaching Hospital   
  ≤30 miles  Reference 
  31-60 miles   1.69 (2.15) 
  61-90 miles   0.60 (2.50) 
  >90 miles  -0.17 (2.64) 
     
 Distance to Nearest ONC HITECH Grantee   
  ≤30 miles  Reference 
  31-60 miles  -1.58 (2.13) 
  61-90 miles   0.32 (2.34) 
  >90 miles  -3.84 (2.52) 
     
 REC Enrollment Rate   
  Q1 (<31.0%)  Reference 
  Q2 (31.0%-50.0%)     -0.12 (1.75) 
  Q3 (50.1%-80.0%)   2.30 (1.84) 
  Q4 (80.1%-100%)   3.33 (1.91) 
    
    
 Covariance Parameter Estimates   
     
  : County-Level Variance 1046.91 1015.69 
     
  : REC-Level Variance 75.81 79.56 
     
     
  : Total Variance 1122.72 1095.25 
      
  Intraclass Correlation (ICC):    
 
   
     
  
0.07   
     
     
     
Boldface values are statistically significant at the P<.05 level. 
EHR – Electronic Health Record 
PCP – Primary Care Provider 
FQHC – Federally Qualified Health Center 
HPSA – Health Professional Shortage Area 
FFS – Fee-for-Service 
ONC – Office of the National Coordinator for Health Information Technology 
HITECH – Health Information Technology for Economic and Clinical Health Act 
REC – Regional Extension Center 
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V. DISCUSSION 
 In 2012, roughly three-quarters of REC-enrolled PCPs had adopted an EHR with 
capabilities that met CMS meaningful use requirements (i.e., ONC certified EHR technology), 
compared with about 40% of primary care physicians nationwide who had adopted a basic EHR 
system.42  These impressive rates of EHR adoption within the REC program may reflect the 
successful efforts of REC program staff to engage, educate, and train health providers and staff 
on the benefits and effective implementation of EHRs.  County-level rates of EHR adoption 
among REC-enrolled PCPs also varied widely across geographic areas.  Most of this variation 
was attributable to differences at the county-level in this study, although differences across 
RECs accounted for 7% of the total variation in county-level EHR adoption.  Thus, there was 
relatively little variation in EHR adoption rates at the REC-level. 
Several area-level factors and population characteristics exhibited strong associations 
with county-level EHR adoption among REC-enrolled PCPs.  Rates of EHR adoption were lower 
in counties with the greatest concentration of minorities and across HPSAs of all types, 
particularly in whole county HPSAs.  This finding is in line with other research on EHR adoption 
in underserved areas,15,17,43 and suggests that PCPs in these counties may face challenges to 
EHR adoption that are not necessarily overcome by engagement with an REC, such as tight 
operating budgets, staff shortages, and limited capacity for integrating EHR training into the 
clinical workflow.44,45  As the administrator of the REC program, ONC should consider 
collaborating with RECs to conduct comprehensive needs assessments among REC-enrolled 
PCPs located in HPSAs and high-minority areas and develop tailored strategies to address the 
specific barriers to EHR adoption faced by these provider groups.    
Consistent with previous research on EHR adoption among FQHC providers,46,47 FQHC 
presence in a county was positively associated with EHR adoption.  This association may be 
due to the range of health IT-related resources that have been offered to FQHCs in recent 
years.  For example, in addition to the technical support services offered by RECs, the Health 
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Resources Services Administration (HRSA) has been very instrumental in providing FQHCs 
with funding and other types of support to facilitate the adoption of health information 
technologies.18 
Of note, EHR adoption rates were comparable across metropolitan and non-metropolitan 
areas, an encouraging finding that runs contrary to evidence from previous studies15,17 and 
suggests that RECs and/or other HITECH initiatives are helping to address the longstanding 
urban-rural divide in EHR adoption. 
Despite previous research documenting negative associations between EHR adoption 
and the proportion of poor and Medicaid patients treated at a facility,15,16 the concentration of 
Medicaid enrollees in a county was positively associated with EHR adoption.  This finding is 
likely attributed to the recent implementation of the Medicaid EHR Incentive Program which 
provides up to $63,750 to Medicaid eligible health professionals who have adopted and/or 
demonstrated meaningful use of a certified EHR system.23  Rates of EHR adoption were 
particularly elevated in counties with the highest concentrations of Medicaid enrollment 
(>25.2%).  Additional analyses also revealed no differences in EHR adoption according to 
county-level poverty concentration after accounting for Medicaid enrollment concentration in the 
county (data not shown).  Thus, it appears that the Medicaid EHR Incentive Program has been 
successful in incentivizing and promoting EHR adoption among a group of providers that has 
historically been less likely to adopt health information technologies.  Future research should 
continue to explore the role of other incentive-based programs in promoting diffusion of best 
practices and medical innovations among providers serving vulnerable patient populations and 
the impact of such programs on disparities.  
The HITECH Act established both EHR adoption incentives and disincentives for 
Medicare providers.  Medicare FFS eligible providers who fail to adopt and demonstrate 
meaningful use of EHRs by 2015 risk payment reductions proportional to the volume of 
Medicare patients they serve.  As a result, providers based in counties with the highest 
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concentrations of Medicare FFS enrollment are more susceptible to such payment reductions.  
Interestingly, Medicare FFS enrollment concentration in counties was not associated with 
county-level EHR adoption among REC-enrolled PCPs; however, county-level Medicare 
Advantage enrollment was positively associated with adoption.   It is unclear whether this 
association is explained by mechanisms related to the Medicare EHR Incentive Program or 
managed care presence in the market; although, past research indicates that providers located 
in markets with higher managed care penetration were more likely to adopt EHRs.16  
 
Limitations  
There are limitations to this study worth noting.  First, this study focuses solely on REC-
enrolled PCPs and not the general population of health providers; thus, it is unclear whether the 
findings from this study would generalize to other health professionals, such as specialist 
providers.  Furthermore, it is possible that REC-enrolled providers differ from the general 
population of providers with respect to geographic location and their willingness to adopt EHRs.  
Additional information on the characteristics and geography of REC-enrolled providers and 
providers not enrolled with an REC would help shed light on whether this study’s findings extend 
to the general population of health providers. 
Second, for reasons related to data unavailability, this study does not consider the 
possible influence of EHR adoption rates among non-REC providers on REC-enrolled providers’ 
adoption patterns.  Because an EHR is a network good with a value that increases as the 
number of users increases, an REC-enrolled health provider based in a county with a higher 
concentration or "critical mass" of health providers with EHRs may be more likely to adopt an 
EHR than her counterpart located in a county that has yet to reach this "critical mass" state.48   
Third, this study is a county-level analysis that does not account for provider- and 
practice-level factors that might contribute to variations in EHR adoption, such as provider age 
and openness to new technologies and practice size and staff composition.  Lastly, it is unclear 
 100 
 
from this study which REC-level factors may be associated with EHR adoption, such as 
organizational characteristics, partnerships, and outreach strategies of RECs; although, the 
observed REC effect on adoption patterns was modest.   
 Despite these limitations, this study adds to the EHR adoption and diffusion literature by 
providing insight into EHR adoption patterns in the context of a large scale federally-funded 
program.  It will be important for future research to assess the direct and indirect impact of 
RECs on EHR adoption across the entire population of health providers.  Moreover, few studies 
have assessed the contribution of area-level factors to the diffusion of EHRs; thus, this study 
helps to fill an important gap in the research literature.  Additional research is needed to 
determine whether these associations hold true for other provider groups. 
 
Conclusion 
Electronic health records have the potential to transform health care delivery by 
facilitating improvements in care quality, continuity, and efficiency.  Recent legislative and 
programmatic efforts to help spur the adoption of EHRs in the US have demonstrated some 
early success; however, some geographic variations in EHR adoption indicate that greater 
attention needs to be paid to ensuring equitable uptake of this form of health information 
technology throughout the US. 
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Appendix Table 4.1 Benjamini-Hochberg (B-H) Adjustment of Race-Associated Odd Ratios from 
Logistic Regression Models Predicting Receipt of Recommended Cancer Care and Survival 
 
  Model 1
†
 Model 2
‡
 p-value for 
significance 
based on 
B-H Criterion 
  Black vs. White Black vs. White 
  
AOR p-value AOR p-value 
Quality Measure      
      
 Curative Surgery for Stage I or II  
Non-Small Cell Lung Cancer 
 
 0.50* <.0001  0.52* <.0001 0.0025 
 3-D CRT or IMRT for Prostate Cancer 
Patients Treated with EBRT 
 
 0.53* <.0001  0.75* 0.0002 0.0050 
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Colon Cancer 
 
 0.80*  <.0001 0.78* 0.0001 0.0075 
 Curative Surgery for Stage I, II, or III 
Rectal Cancer 
 
 0.57* 0.0004  0.57* 0.0023 0.0100 
 Three-Year All Cause Survival for 
Colon Cancer ¶ 
 
 0.75* 0.0013 0.78* 0.0166 0.0125 
 Three-Year All Cause Survival for 
Rectal Cancer ¶ 
 
 0.61* 0.0074 0.66* 0.0495 0.0150 
 Use of Potent Antiemetics for  
Highly-Emetogenic Chemotherapy 
 
 0.87* 0.0161 0.95 0.4771 0.0175 
 Adjuvant Chemotherapy for Stage III 
Colon Cancer  
 
0.75* 0.0339 0.87 0.3709 0.0200 
 Curative Surgery for Stage I, II, or III 
Colon Cancer 
 
0.76* 0.0367 0.82 0.2152 0.0225 
 Oral Anti-Androgen before Initiating 
GnRH Agonist Therapy for Metastatic 
Prostate Cancer 
 
1.34* 0.0431 0.99 0.9750 0.0250 
 Chemotherapy and/or Radiation for 
Resected Stage IIIA Non-Small Cell 
Lung Cancer 
 
1.67 0.1323 1.35 0.4684 0.0275 
 Mediastinal Evaluation for Stage I or II 
Non-Small Cell Lung Cancer 
 
0.75 0.1329 0.92 0.7200 0.0300 
 Adjuvant Chemotherapy and Radiation 
Therapy for Stage II or III  
Rectal Cancer 
 
1.49 0.1438 1.39 0.3104 0.0325 
 One-Year All Cause Survival for  
Non-Small Cell Lung Cancer 
 
1.06 0.1731 1.05 0.2671 0.0350 
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 Appendix Table 4.1 (Continued)      
       
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Rectal Cancer 
 
0.87 0.2621 0.87 0.3248 0.0375 
 Androgen Ablation within 120 Days for 
Men with Stage IV Prostate Cancer 
 
1.08 0.5587 0.99 0.9318 0.0400 
 Prescription of Narcotic Pain 
Medication for Advanced Cancer 
Patients in Pain 
 
1.04 0.7250 1.04 0.7235 0.0425 
 One-Year All Cause Survival for  
Small Cell Lung Cancer 
 
1.04 0.7330 1.07 0.6308 0.0450 
 Chemotherapy and Radiation for 
Limited-Stage Small Cell Lung Cancer 
 
0.96 0.8299 0.80 0.3285 0.0475 
 Adjuvant Androgen Deprivation 
Therapy for High-Risk Cancers 
Treated with Radiation Therapy 
 
1.01 0.8927 0.86 0.1220 0.0500 
       
  
AOR – Adjusted Odds Ratio  
GnRH – Gonadotropin Releasing Hormone  
3-D CRT – 3-Dimensional Conformal Radiation Therapy 
IMRT – Intensity Modulated Radiation Therapy 
EBRT – External Beam Radiation Therapy 
†  Model 1 corresponds to adjusted logistic regression models excluding hospital fixed effects  
‡  Model 2 corresponds to adjusted logistic regression models including hospital fixed effects  
All models adjusted for age, sex (except prostate cancer models), marital status, prior cancer history, 
Charlson comorbidity score, and year of diagnosis.  Lung cancer models also included chronic 
obstructive pulmonary disease (COPD) as a covariate, and for this group the Charlson score was 
calculated without COPD. Treatment and survival models adjusted for tumor grade and stage, and 
survival models also adjusted for tumor size. Palliative/supportive care models adjusted for  
cancer type.   
 
* indicates AOR is statistically significant at p<.05 
Boldface* indicates AOR is statistically significant after applying Benjamini-Hochberg multiple 
comparisons adjustment  
 
¶ Three-year survival for colon and rectal cancers captures patients diagnosed during 2001 & 2002 
 
 
  
 107 
 
Appendix Table 4.2 Adjusted (including Socioeconomic Status) Race-Associated Odd Ratios from 
Logistic Regression Models Predicting Receipt of Recommended Cancer Care and Survival  
 
 
 
 
Model 
1†
 Model 2
‡
 
  Black vs. White Black vs. White 
  AOR [95% CI ] AOR [95% CI ] 
Quality Measure   
   
   Colon Cancer 
 
 
 
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Colon Cancer 
 
  0.80 [0.71, 0.90]*   0.78 [0.69, 0.89]* 
 Early Stage (Stage I/II vs. III/IV) at 
Presentation, Rectal Cancer 
 
0.86 [0.67, 1.11] 0.85 [0.64, 1.13] 
 Curative Surgery for Stage I, II, or III  
Colon Cancer 
 
  0.72 [0.54, 0.95]* 0.76 [0.55, 1.06] 
 Curative Surgery for Stage I, II, or III  
Rectal Cancer 
 
  0.62 [0.44, 0.88]*   0.61 [0.41, 0.89]* 
 Adjuvant Chemotherapy for Stage III  
Colon Cancer 
 
0.83 [0.63, 1.11] 0.93 [0.68, 1.28] 
 Adjuvant Chemotherapy and Radiation 
Therapy for Stage II or III  
Rectal Cancer 
 
1.59 [0.91, 2.78] 1.53 [0.79, 2.96] 
 Three-Year All Cause Survival for  
Colon Cancer ¶ 
 
  0.77 [0.63, 0.93]*   0.79 [0.64, 0.98]* 
 Three-Year All Cause Survival for  
Rectal Cancer ¶ 
 
  0.64 [0.43, 0.93]* 0.69 [0.45, 1.07] 
   Lung Cancer 
 
 
 
 Curative Surgery for Stage I or II  
Non-Small Cell Lung Cancer 
 
  0.57 [0.47, 0.70]*   0.57 [0.45, 0.72]* 
 Mediastinal Evaluation for Stage I or II  
Non-Small Cell Lung Cancer 
 
0.77 [0.52, 1.15] 0.91 [0.57, 1.45] 
 Chemotherapy and/or Radiation for 
Resected Stage IIIA Non-Small Cell 
Lung Cancer 
 
1.56 [0.77, 3.16] 1.16 [0.48, 2.79] 
 Chemotherapy and Radiation for  
Limited-Stage Small Cell Lung Cancer 
 
1.11 [0.74, 1.67] 0.87 [0.54, 1.39] 
 One-Year All Cause Survival for  
Non-Small Cell Lung Cancer 
 
  1.16 [1.03, 1.22]* 1.09 [0.99, 1.19] 
 One-Year All Cause Survival for  
Small Cell Lung Cancer 
1.13 [0.87, 1.47] 1.12 [0.85, 1.47] 
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Appendix Table 4.2 (Continued)   
   
   Prostate Cancer 
 
 
 
 Androgen Ablation within 120 Days for 
Men with Stage IV Prostate Cancer 
 
1.08 [0.82, 1.41] 1.01 [0.73, 1.41] 
 Oral Anti-Androgen before Initiating 
GnRH Agonist Therapy for Metastatic  
Prostate Cancer 
 
1.13 [0.83, 1.54] 0.82 [0.56, 1.18] 
 Adjuvant Androgen Deprivation 
Therapy for High-Risk Cancers 
Treated with Radiation Therapy 
 
1.02 [0.87, 1.20] 0.89 [0.73, 1.08] 
 3-D CRT or IMRT for Prostate Cancer  
Patients Treated with EBRT 
 
  0.54 [0.48, 0.61]*   0.78 [0.67, 0.91]* 
   Palliative/Supportive Care 
 
 
 
 Use of Potent Antiemetics for  
Highly-Emetogenic Chemotherapy 
 
0.90 [0.80, 1.00] 0.95 [0.82, 1.10] 
 Prescription of Narcotic Pain 
Medication for Advanced Cancer 
Patients in Pain 
 
1.03 [0.84, 1.27] 1.06 [0.84, 1.34] 
  
   
AOR – Adjusted Odds Ratio   
GnRH – Gonadotropin Releasing Hormone   
3-D CRT – 3-Dimensional Conformal Radiation Therapy 
IMRT – Intensity Modulated Radiation Therapy 
EBRT – External Beam Radiation Therapy 
†  Model 1 corresponds to adjusted logistic regression models excluding hospital fixed effects   
‡  Model 2 corresponds to adjusted logistic regression models including hospital fixed effects   
All models adjusted for age, sex (except prostate cancer models), marital status, area-level 
socioeconomic status based on the zip code of the patient’s residence (median household income, the 
percentage of college graduates, and the percentage of persons living below the poverty level), prior 
cancer history, Charlson comorbidity score, and year of diagnosis.  Lung cancer models also included 
chronic obstructive pulmonary disease (COPD) as a covariate, and for this group the Charlson score 
was calculated without COPD. Treatment and survival models adjusted for tumor grade and stage, and 
survival models also adjusted for tumor size. Palliative/supportive care models adjusted for  
cancer type.   
  
* indicates AOR is statistically significant at p<.05 
Boldface* indicates AOR is statistically significant after applying Benjamini-Hochberg multiple 
comparisons adjustment  
  
¶ Three-year survival for colon and rectal cancers captures patients diagnosed during 2001 & 2002 
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Appendix Table 4.3 Types of Composite Measure Scoring Techniques 
 
Method Description 
  
All-or-None Process Measures 
 
Performance is defined by the proportion of patients receiving all of 
the specified care processes for which they were eligible. No credit 
is given for patients who receive some but not all required items. 
Any-or-None Similar to-all-or none but is used for events that should not occur.  
A patient is counted as failing if he or she experiences at least 1 
adverse outcome from a list of 2 or more adverse outcomes. 
Linear Combinations Can be simple average or weighted average of individual measure 
scores. 
Regression-Based Composites If a certain outcome is regarded as a gold standard, the weighting 
of individual items may be determined empirically by optimizing the 
predictability of gold standard end-point. 
Opportunity Scoring This approach counts the number of times a given care process 
was actually performed (numerator) divided by the number of 
chances a provider had to give this care correctly (denominator). 
Unlike simple averaging, each item is implicitly weighted in 
proportion to the percentage of eligible patients, which may vary 
from provider to provider. 
 
Source: Centers for Medicare and Medicaid Services, 2012 
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Appendix Table 4.4 Electronic Health Record Meaningful Use Criteria 
 
Stage 1 (2011-2012)  Stage 2 (2014)  Stage 3 (2016) 
Data Capture and Sharing   Advance Clinical Processes   Improved Outcomes 
     
Electronically capturing health 
information in a standardized 
format 
 More rigorous health 
information exchange (HIE) 
 Improving quality, safety, and 
efficiency, leading to 
improved health outcomes 
Using that information to track 
key clinical conditions 
 Increased requirements for e-
prescribing and incorporating 
lab results 
 Decision support for national 
high-priority conditions 
Communicating that 
information for care 
coordination processes 
 Electronic transmission of 
patient care summaries across 
multiple settings 
 Patient access to self-
management tools 
Initiating the reporting of 
clinical quality measures and 
public health information 
 More patient-controlled data  Access to comprehensive 
patient data through patient-
centered HIE 
Using information to engage 
patients and their families in 
their care 
   Improving population health 
          
 
Source: Office of the National Coordinator for Health IT 
  
 111 
 
Appendix Table 4.5 List of Regional Extension Centers and Funding 
 
Regional Extension Center Grantee State 
Federal 
Share 
Additional 
Funding in 
2011 
    
Alabama Regional Extension Center AL $7,519,969 $404,806 
Alaska eHealth Network AK $3,632,357 $604,446 
Altarum Institute MI $19,619,990  
Arizona Health e-Connection (AzHeC) AZ $10,791,644 $403,131 
Arkansas Foundation for Medical Care, Inc. AR $7,400,000 $404,775 
California Regional Extension Center (North) CA $17,286,081 $600,227 
California Regional Extension Center (South) CA $13,961,339 $672,913 
CalOptima Foundation CA $4,662,426 $1,187,574 
Chesapeake Regional Information System for Our 
Patients 
MD $5,535,423 $869,352 
Chicago Health Information Technology Regional 
Extension Center (CHITREC) 
IL $7,649,533 $621,719 
CIMRO of Nebraska NE $6,647,371 $402,404 
Colorado Regional Health Information Organization 
(CORHIO) 
CO $12,475,000 $404,775 
Community Health Centers Alliance, Inc.* FL $11,078,879 $262,934 
Dakota State University SD $5,687,168 $568,142 
Dallas-Fort Worth Hospital Council Education and 
Research Foundation 
TX $8,488,513 $406,262 
eHealth Connecticut CT $5,749,309 $695,601 
eHealth DC DC $5,488,437 $854,623 
eQHealth Solutions, Inc. MS $4,289,613 $954,585 
Greater Cincinnati Health Bridge OH, KY, IN $9,738,000 $361,775 
Health Choice Network of Florida, Inc.* FL $12,998,040 $404,775 
Health Information Exchange 
HI and Pacific 
Territories 
$5,859,716 $545,059 
HealthInfoNet ME $4,777,483 $836,275 
HealthInsight UT, NV $6,917,783 $151,217 
HITEC-LA CA $15,625,910 $778,865 
IFMC IA $5,508,019  
Kansas Foundation for Medical Care, Inc. (KFMC) KS $7,000,000 $404,775 
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Appendix Table 4.5 (Continued)    
Louisiana Health Care Quality Forum LA $6,207,802 $406,973 
Lovelace Clinic Foundation-LCF Research NM $6,175,000 $404,775 
Massachusetts eHealth Collaborative, Inc. NH $5,105,495 $1,211,814 
Massachusetts Technology Park Corporation MA $13,433,107 $406,668 
MetaStar, Inc. WI $9,125,000 $404,775 
Morehouse School of Medicine GA $19,521,542 $89,012 
Mountain-Pacific Quality Health Foundation 
(MPQHF) 
MT, WY $5,020,754 $1,384,021 
National Indian Health Board (NIHB) 
DC, Serving 
Nationwide 
Indian Country 
$15,625,910 $403,865 
New Jersey Institute of Technology (NJIT) NJ $23,048,351 $765,241 
New York eHealth Collaborative (NYeC) NY $26,534,999 $404,776 
Northern Illinois University IL $7,546,000 $358,775 
NYC REACH NY $21,754,010 $179,700 
OCHIN, Inc. OR $13,201,499  
Ohio Health Information Partnership (OHIP) OH $28,500,000  
Oklahoma Foundation for Medical Quality, Inc. 
(OFMQ) 
OK $5,331,685 $667,547 
PaperFree Florida FL $5,884,132 $520,643 
Ponce School of Medicine PR $19,280,796 $2,259,154 
Purdue University IN $12,000,000 $404,775 
Qsource TN $7,256,155 $328,283 
Qualis Health WA, ID $12,846,482  
Quality Insights of Delaware DE $5,859,716 $260,891 
Quality Insights of Pennsylvania, Inc. (Eastern) PA $28,810,271 $1,094,504 
Quality Insights of Pennsylvania, Inc. (Western) PA $15,625,910 $778,865 
Rhode Island Quality Institute (RIQI) RI $6,000,000 $404,775 
South Carolina Research Foundation SC $5,581,407 $823,368 
Stratis Health MN, ND $19,000,000 $289,040 
Texas Tech University Health Sciences Center TX $6,666,296 $403,479 
The Curators of the University of Missouri MO $6,836,335 $403,440 
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The TAMUS Health Science Center Research 
Foundation 
TX $5,279,970 $1,124,805 
University of Central Florida FL $7,669,328 $207,731 
University of Kentucky Research Foundation KY $6,005,467 $399,308 
University of North Carolina AHEC REC NC $13,569,169  
University of Texas Health Science Center at 
Houston 
TX $15,274,327 $405,448 
Vermont Information Technology Leaders, Inc. VT $6,762,080 $142,695 
VHQC (Virginia Health Quality Center) VA $12,425,000 $404,775 
West Virginia Health Improvement Institute, Inc. WV $6,000,000 $404,775 
    
 
Source: Office of the National Coordinator for Health IT 
